



Myelofibrosis (MF) is a clonal disorders of hematopoietic stem cells. Mutations in 3 genes 
(JAK2, CALR, MPL) and chronic inflammation are the hallmark of MF. Triple negative patients 
(TN) are negative to all three mutations. In addition to molecular aberrations, MF is characterized 
by specific abnormalities in the development of megakaryocytes and platelet activation and immune 
dysfunction. In this scenario, infectious complications are the leading cause of morbidity and 
mortality. Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, suppresses both clonal 
myeloproliferation and release of proinflammatory cytokines, reducing splenomegaly and 
constitutional symptoms in around 50% of patients (pts). RUX exerts also immunosuppressive 
activity, resulting in increased infectious risk in RUX-treated MF pts.  
Inflammation plays a role in cancer and MF. However, the crosstalk between normal hemopoietic 
stem/progenitor cells HSPC) and their inflammatory microenvironment is largely elusive. 
Circulating microvesicles (MVs; 0.1-1 µm), which are part of the inflammatory network, are small 
vesicles deriving from the cell plasma membrane with a role in intercellular communication. They 
are increased in inflammation and cancer, including MF. Most of circulating MVs are of platelet 
(PLT) and megakaryocyte (MK) origin. However, their pathogenetic role in the inflammatory 
microenvironment of MF is still elusive.  
Furthermore, even though previous studies described immune dysfunction in pts with MF, it is still 
unknown whether the atypical infectious events are caused by specific deficit in the innate or 
adaptive immune response and whether RUX therapy may impact the monocyte (MO)
 
Based on this background, the main aim of my PhD project was the functional characterization of 
the immune/inflammatory microenvironment of MF. Specific aims were: 1) to analyze the effects of 
inflammation on the functional behavior of normal HSPC; 2) to characterize the bio-molecular 
profile of circulating MVs in MF; 3) to functionally characterize the circulating immune 
microenvironment of MF and 4) to investigate the role of circulating MO in the inflammatory 
microenvironment of JAK2V617F mutated MF pts and evaluate whether and to what extent RUX may 
influence their in vitro/in vivo behaviour. 
 Focusing on the functional effects of the inflammatory microenvironment on the HSPC
compartment, we show that various combinations of inflammatory cytokines promote the in vitro 
survival of CD34+ cells from umbilical cord and increase proliferation/clonogenicity and in vitro 
migration of CD34+ cells from G-CSF-mobilized peripheral blood. We demonstrated that normal 
CD34+ cells from two different sources show distinctive response to inflammatory factors and that 
the balance between pro/anti-inflammatory signals play a very important role in the functional 
behaviour of normal CD34+ cells. 
 Focusing on the functional role of circulating MVs in MF, the results show that 1) the 
circulating MK/PLT-MVs profile is altered; 2) according to IPSS score, Intermediate 2/high risk pts
show respectively reduced/increased MK/PLT-MVs proportion as compared with the 
intermediate1/low risk pts; 3) at baseline spleen-responders (SR) pts show a significant increased 
MK-MVs proportion as compared with the non-responder (NR) counterparts; importantly, a cut-off 
value below 19.95% of MK-MVs predicted the NR pts. Interestingly, RUX therapy restores the 
normal MK/PLT-MVs profile in SR pts only. On this basis, the circulating MK/PLT-MVs could 
have a diagnostic and prognostic role in MF.  
 Finally, focusing on the immune microenvironment of MF, the results of this thesis 
demonstrate that 1) there are phenotypic/functional alterations in key immune cell subsets such as
reduced ability of monocyte to differentiate into dendritic cells, reduced plasticity of Th17 
lymphocytes and reduced functional capacity of Innate Lymphoid Cells. Furthermore, selected
immune defects were mainly associated with the presence of the JAK2V617F or CALR mutation; 2) 
circulating MO show an altered activation/differentiation program and a reduced in vitro capacity to 
produce/secrete inflammatory cytokines in response to an infectious stimulus. Importantly, at 
variance with previous studies on T cells, RUX improves intracellular pro-inflammatory cytokines
production of MF-MO and promotes the release of inflammatory cytokines associated with MO-
derived-MVs in response to an infectious stimulus. Overall, these immune system abnormalities 
could contribute to the development of an immunodeficiency state with the potential to promote 
immune evasion, cancer progression and increased susceptibility to infection. These findings further
contribute to better understand immune biology in the setting of the MF and refines the biological 
effects of RUX, suggesting that RUX activity is cell type-dependent. 
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1.1 Clinical features 
 
The Myeloproliferative Neoplasms (MPN), including Essential Thrombocythemia (ET), 
Polycythemia Vera (PV) and Myelofibrosis (MF), are clonal disorders of the hematopoietic stem
cells characterized by a myeloid proliferation driven by at least one somatically acquired driver
mutation in JAK2, MPL, and CALR genes. Regardless of driver mutations, the JAK-STAT 
signalling pathway is hyperactivated in all MPNs (1). The World Health Organization (WHO) 
classification system for hematopoietic tumors was recently revised and the 2016 document 
recognizes several major categories of myeloid malignancies including acute myeloid leukemia 
(AML) and related neoplasms, myelodysplastic syndromes (MDS), MPN, MDS/MPN overlap, 
d neoplasms with recurrent mutations 
involving PDGFRA, PDGFRB, FGFR1, and , and myeloid neoplasms with germline 
predisposition. Within the WHO MPN category, PV, ET and primary (PMF) are grouped together 
.
. Somatic mutations in MPN, including 
s; the former include mutations in JAK2, 
CALR and MPL genes and the latter mutations in genes mainly regulating methylation and splicing.
It is generally believed that driver mutations are essential for the MPN phenotype whereas the 
t contribute to disease progression and leukemic transformation (2). 
MF is a blood cancer with an incidence of about 0.58 new cases per 100.000 person-years, 
but with a much higher prevalence because of a chronic and disabling course leading always to 
death due to progression, disease-related or treatment-related complications. MF patients suffer 
from debilitating systemic symptoms, progressive splenomegaly and transfusion-dependent 
cytopenias. They also experience increased risk of thrombosis, second neoplasia, and evolution to 
acute leukemia. It is mainly characterized by a clonal myeloproliferation and medullary fibrosis, 
with consequent insufficiency and delocalization of medullary hemopoiesis at the spleen and liver 
level (splenomegaly and hepatomegaly). Bone marrow fibrosis is mainly caused by the expansion 
of monocytes, which secrete pro-angiogenetic factors (3) and megakaryocyte contribution (   )..
Inefficient hematopoiesis leads to a lower production of red blood cells (anemia), an impaired 
megakaryocytopoiesis (thrombocytopenia or thrombocytosis), platelet activation, an increase of 
immature granulocytes and the appearance of myeloid precursors in the peripheral blood.
Constitutional symptoms such as fatigue, dyspnoea, night sweats and fever are also observed (4). 
The diagnosis of MF is based on the observation of bone marrow morphology and on the search for 
the three "driver mutations" (JAK2, MPL, CALR). Based on histological analysis of the bone 








Fig 1: Examples of bone marrow sections of patients with MF (6). 
 
 
The International Prognostic Scoring System (IPSS) risk score was designed in 2009 for use in the 
initial diagnosis and risk stratification of PMF patients according to the following prognostic 
factors: 1- age (above 65 years); 2- presence of constitutional symptoms; 3-hemoglobin levels 
(lower than 10 g/dL); 4- leukocyte count (higher than 25×109/L); 5- percentage of circulating blasts 
(higher or equal than to 1%).  
Based on these factors, MF patients can be subdivided into 4 categories: 
 (0 adverse factors) 
 (1 adverse factors) 
 (2 adverse factors) 
( )  




Fig 2: Stratification of patients according to the IPSS risk score (7). 
 
 
The IWG-MRT subsequently developed a dynamic prognostic model (DIPSS) that utilizes the same 
prognostic variables used in IPSS but can be applied at any time during the disease course and used 
to predict the survival of the patients during the follow-up (8). The DIPSS prognostic score was 
then further extended to the DIPSS plus model, which also considers the patient's karyotype, 
platelet count and transfusion status (9). 
 
 
Fig 3: Prognostic models in MF (10). 
 
In recent years two new prognostic scores have been developed: GIPSS (genetically-inspired 
prognostic scoring system) and MIPSS70 + version 2.0 (mutation- and karyotype-enhanced 
international prognostic scoring system) (5). 
The GIPSS prognostic score estimates the risk based on the mutational status. The cytogenetic 
aspects, the presence of the three driver mutations (JAK2, MPL, CALR) and other additional 
mutations (ASXL1, SRSF2, U2AF1Q157) are also taken into consideration (11). Finally, the MIPSS 
70+ prognostic score, used for patients with age eligible for hematopoietic stem cell transplant, 
includes the presence of various mutations (such as ASXL1, SRFR2, EZH2, IDH1, IDH2, CALR) 
and, at the same time, six clinical parameters (hemoglobin level, lymphocyte count, percentage 
circulating blasts, degree of medullary fibrosis, constitutional symptoms) (12). Based on the risk 
estimation, a different therapeutic approach is applied. A therapeutic option is the allogeneic stem 
cell transplant, which is recommended for high risk subjects. Patients with intermediate and low 
risk are treated with conventional therapy, including thalidomide, danazol, hydroxyurea and 
inhibitors of JAK1/2 (5). 
 
 





Fig 5: GIPSS-based treatment algorithm of MF (11). 
 
 
1.2 Molecular pathogenesis 
 
The molecular pathogenesis of MF relies on 3 driver mutations in JAK2, MPL and CALR genes. The first 
identified mutation (in 2005) was the JAK2V617F, a gain-of-function mutation, caused by the 
replacement of a valine with a phenylalanine in position 617 (V617F) (14). JAK2 is a tyrosine 
kinase belonging to a large family of similar proteins that, in mammals, includes JAK1, JAK2, 
JAK3, JAK4 (15). The gene coding for JAK2 is placed in position 9p24.1 26 and has 26 exons (16). 
Physiologically, JAK plays a fundamental role in signal transduction that occurs when a cytokine or 
a growth factor interacts with its receptor. When the JAK kinase is activated, it phosphorylates the 
STAT substrate by starting a fundamental signal pathway (JAK/STAT) involved into proliferation, 
survival and inhibition of apoptosis. JAK2 can also activate other downstream pathways, such as 









To perform its crucial task, the kinase JAK2 is formed by two protein domains: a kinase domain 
(JH1 domain), which phosphorylates the downstream substrates allowing signal transduction and a 
pseudokinase domain (JH2 domain) with an inhibitory role against the kinase domain. According to 
some recent studies, the pseudokinase domain is able to phosphorylate two residues of the JAK2 
protein (Ser523 and Tyr570), generating a conformational change that makes the kinase inactive. 
So, the JAK2 protein has an important feedbeck-negative regulation system (18).  
 
 
Fig 7: JAK2 protein domains (19) 
 
The JAK2V617F mutation falls at the level of this regulatory domain (specifically in exon 14), thus 
causing a constitutive hyperactivation of the kinase. Therefore, the cell carrying this type of
mutation is essentially independent of the stimulation of cytokines and growth factors, with 
consequent clonal proliferation (20). Other mutations have also been reported in other positions of 
the JAK2 gene, such as a mutation in exon 12 (21). At the cellular level, the effect of these 
mutations is substantially the same as the JAK2V617F mutation.  
The second driver mutation identified in MPN was detected in the MPL gene. This gene, 
placed in 1p34.2 position of the human genome, encodes the Thrombopoietin receptor, the most 
important regulatory factor of megakaryocytopoiesis and platelet formation. Once the ligand binds 




Fig 8: The TPO/MPL pathway (23). 
 
The MPL mutation consists in the substitution of a tryptophan in 515 position with another 
aminoacid 
cases, there is an abnormal constitutive activation of the MPL receptor (in the absence of the ligand) 
with consequent activation of the JAK/STAT pathway (24).  
Finally, another mutation in the Calreticulin gene (CALR) was recently discovered. This 
gene, which is on chromosome 19p13.13, encodes a protein implicated in intracellular calcium 
homeostasis (transport of calcium from the endoplasmic reticulum) and in the correct "folding" of 
proteins; however, it can also play a role as a transcription factor (25). The Calreticulin protein is 
present at the intracellular, extracellular or transmembrane level. It is a very versatile protein, with 






Fig 9: The structure of the Calreticulin protein (27) 
 
 
Mutations in the CALR gene are generally deletions or insertions that usually fall into exon 9. There 
are two types of mutations of the CALR gene: 
- Type 1: deletion of 52 base pairs 
- Type 2: insertion of 5 base pairs 
Both mutations affect the C-terminal domain of the protein (28). 
 
 
Fig 10: The mutated Calreticulin: type 1 and 2 (29) 
 
According to Araki M. et al. and Elf S et al., the mutated Calreticulin undergoes a conformational 
change that allows it to interact with the MPL receptor, inducing a signal transduction via 
JAK/STAT in the absence of the ligand (Thrombopoietin). In particular, the mutated Calreticulin 
would bind the extracellular part of the MPL receptor, determining its constitutive activation (30, 
31). 
Therefore, constitutive activation of the JAK/STAT signalling pathway is key to the development of 
the MF phenotype in all mutant backgrounds. JAK2V617F mutations can drive MF through activation 
of erythropoietin receptor (EPOR), thrombopoietin receptor (MPL) and granulocyte-colony 
stimulating factor receptor (G-CSFR) receptors present on different stages of a maturing myeloid 
cell.  Clonal dominance of homozygosity or heterozygosity of JAK2V617F, the presence and order of 
acquisition of co-operating mutations and additional factors such as iron deficiency and gender can 
impact on the resulting phenotype. CALR and MPL mutations result in a PMF phenotype through 
activation of the MPL receptor. All drivers mutations appear to be largely mutually exclusive 
although bi-clonal disease can occur.  JAK2 V617F and CALR mutations are detectable in the long 
term haematopoietic stem cell (LT-HSC) population and in all maturing stages of the 
haematopoietic hierarchy. Yet, these JAK2 V617F LT-HSC population appear to exhibit reduced 
self-renewal and are skewed towards expansion of the progenitor pool instead (32). 
In addition to the 3 driver mutations (JAK2, MPL and CALR), a range of genes are 
repeatedly found to be mutated in MF. These co-operating oncogenic mutations found alongside the 
driver mutations include genes involved in cell signalling pathways (LNK, CBL, NRAS and NF1), 
epigenetic regulation (ASXL1, EZH2, TET2, DNMT3A, IDH1 and IDH2), transcriptional regulation
(TP53, RUNX1) and mRNA processing (SF3B1, SRSF2, U2AF1, ZRSR2) (32). The most mutated 
genes are TET2, ASXL1, DNMT3A, CBL, LNK, IDH1/2, IKF1, EZH2, TP53, SRSF2 (28). This 
creates a general genetic instability that characterizes and complicates the MF framework. As 
shown in Fig. 10, around 60% of MF patients carry the JAK2V617F mutation, 30% are CALR
mutated and 8% are MPL mutated (33). However, there is a small group of patients (around 10%) in 






Fig 11: The distribution of the driver  mutations in MPN (34). 
 
As demonstrated by Tefferi et al., the mutational spectrum of MF patients is correlated with 
survival. The triple-negative  patients have the lowest survival (with an average of 2.3 years), 
while the CALR mutated patients have the highest (with an average of 15.9 years). Mutations in 
JAK2 and MPL genes respectively confer an average life expectancy of 5.9 years and 9.9 years (35). 
 
 
Fig 12: Survival of patients with MF according to mutational status (35). 
 
 
In addition, the allelic burden of the JAK2 mutation (more than 56.7%) is associated with increased 
disease severity and increased risk of thrombosis in patients with MF (3, 36). 
 
2. Inflammatory pathogenesis in MF 
 
Chronic inflammation is the hallmark of MF. We know that inflammation has a protective 
role; however, in some cases, it can become harmful. Some authors describe "oncoinflammation", 
referring to the relationship between tumour cells and inflammatory microenvironment (37).  
Cytokines are soluble proteins, commonly known for their immunomodulatory functions,
that orchestrate both innate immunity and adaptive immunity. In addition to classically defined
cytokines, such as interleukins and interferons, a variety of other soluble factors, including a range 
of growth factors, have been often classified as cytokines. Generally, cytokines are produced in 
response to cellular stresses including pathogen infections, inflammation, or injury. Their release 
exerts effects on different types of somatic cells by modulating different types of response. In case 
of infections or inflammations, monocytes, macrophages and neutrophils infiltrate and secrete 
numerous cytokines locally, including a variety of angiogenic factors, growth factors, and proteases.
This results in a variety of cellular responses including increased angiogenesis, cell proliferation, 
migration of cells, and haematopoiesis (38) The immune response is mediated by the early reactions 
of innate immunity and other later ones of adaptive immunity. The innate immunity consists of 
cellular and biochemical defence mechanisms pre-existing to infection and ready to react quickly. 
In the context of innate immunity, the cytokines guarantee a rapid response from the leucocytes but 
also from the parenchymal cells, which are able to identify a pathogen by toll like receptor (TLR)
expression. The main cytokines in this category are Interleukins (IL)-1, 6, 12, 18 (CXCL8), Tumor 
necrosis factor (TNF)- , Granulocyte/Granulocyte-macrophage colony stimulating factor (G-CSF, 
GM-CSF). They activate a series of fundamental cells for innate immunity (monocytes, dendritic
cells, T cells, NK etc.) as well as the processes aimed at the elimination of the pathogen (chemokine 
release, increase of adhesion molecules expression at the endothelial level, increased fluidity of 
blood etc.) (39).This category of cytokines is also called inflammatory cytokines because they 
induce an inflammatory state. Regarding adaptive immunity, one of the fundamental roles of 
cytokines is to guide the T-cell response, for example IL-12 induce a TH1-type response, resulting 
in the production of effector cytokines (interferon (IFN)- -
induced by IL-4 production with consequent activation of the humoral response and IgE production
(40). 
Some cytokines have a negative regulatory role of immunity. They can be defined as anti-
inflammatory cytokines. The suppression of the immune response is mainly driven by IL-10 and 
Transforming Growth Factor (TGF)-  
They are produced by many cell type (monocytes, dendritic cells, T cells, regulatory T-cell (Treg)
NK, etc) (41). 
 The released cytokines, both pro-inflammatory and anti-inflammatory, act to control cellular stress 
and minimize tissue damage. In general, after the resolution of the lesion or the inflammatory state, 
the cytokines return to the homeostatic levels. However, it is increasingly clear that chronic 
inflammation, resulting in abnormal production and dysregulation of cytokine levels, contributes to 
the pathogenesis of various diseases including cancer (42). 
MF is typically characterized by a high level of proinflammatory cytokines both in the bone 
marrow and in the system. The constitutive activation of the JAK/STAT pathway leads to the 
excessive production of pro/anti-inflammatory cytokines. Therefore, a complex inflammatory 
microenvironment, supported by the activation of the JAK/STAT pathway, is created (43). These 
pro-inflammatory cytokines result from both mutant haematopoietic MPN clones and non mutant 
haematopoietic cells as a direct result of JAK/STAT signalling (44). 
Recent studies have examined the circulating levels of pro/ anti-inflammatory cytokines in patients 
with MF and have studied their prognostic significance. Various pro-inflammatory cytokines such 
as TNF-alpha, IL-6, IL-8, IL-  are elevated in the circulation. It has also been shown that IL-8 and 
IL-2 receptor (IL-2R) are prognostic indicators of reduced survival and leukemic transformation 
(45). In particular, IL-8 can contribute to the development of the tumour microenvironment through 
its important role in angiogenesis and in the proliferation of endothelial cells (46).  
 
 
Fig 13: Increased survival of patients with normal levels of IL-8 and IL-2R (blue) as compared to patients 
with one / both cytokines increased in plasma (yellow)(45). 
 
Skov et al., based on the study of the gene expression profile of whole blood in patients with MF, 
has shown upregulation of genes involved in inflammation and immunity, including Vascular 
Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF), G-CSF, monokine induced 
by IFN- MIG). In particular, high levels of growth factor such as Platelet Derived Growth Fcator 
(PDGF), Fibroblast Growth Factor (FGFB) and VEGF have been implicated in fibrosis and 
angiogenesis. Furthermore, the expression of bone morphogenetic proteins (BMP), such as BMP1, 
BMP6, and BMP7, were higher in patients with advanced stages of MF (47). Increased BMP6 
expression was also observed in the pre-fibrotic phases of MF. It has been suggested that 
progressive medullary fibrosis may be promoted by synergism between fibronectin and 
proinflammatory cytokines such as TGF- 1 and IL-1. Hoermann et al. has shown that the level of 
oncostatin M, a pleiotropic cytokine involved in a variety of physiological contexts including 
hematopoiesis, is elevated in JAK2V617F-positive patients and this is mutation-linked. The authors 
concluded that overexpression of oncostatin M plays a role in bone marrow fibrosis and neo-
angiogenesis of the bone marrow microenvironment and furthermore, amplifies cytokine production 
contributing to the cytokine storm observed in patients with MF (48). 
Splenomegaly in MF is associated with the migration of CD34+ stem/progenitor cells from the 
bone marrow to the spleen and it is supposed to be the result of the clonal expansion of neoplastic 
stem cells, associated with high levels of cytokines. Consistently, high number of CD34+ cells is 
observed in the peripheral blood of MF patients. The presence of the JAK2V617F mutation in both the 
bone marrow cells and the spleen confirms clonality. In addition, TNF-alpha, a cytokine known to 
be associated with clonal evolution and the selection of preleukemic stem cells in Fanconi anemia, 
is also associated with clonal expansion in MF and therefore splenomegaly. Many other cytokines, 
including HGF, MIG and IL-1RA have been associated with marked splenomegaly (49). 
Frequent symptoms reported by patients with MF, such as night sweats and itching, are caused by 
high levels of cytokines, and more particularly, high circulating IL-8 levels have been associated 
with severe constitutional symptoms. 
Based on in vitro studies and animal models, it has been hypothesized that chronic inflammation 
plays an important role in the initiation and progression of MF. It has been hypothesized that 
chronic inflammation can promote genetic instability and mutations (50) and may contribute to 
select the malignant clone and promote disease progression to leukemia (51). 
More recently, it has been observed that, in addition to TNF- the Tissue Inhibitor of 
Metalloproteases (TIMP1-inhibitor of metalloproteases) are present at high levels in the blood of 
patients with MF (both JAK2 and CALR mutated). When combinations of these three factors are 
added in culture in vitro, a significant increase in survival, migration and clonogenic capacity of 
circulating CD34+ cells of patients with MF is observed (52).  
Interestingly, pre-existing inflammatory diseases, such as Crohn's disease or autoimmune diseases, 
can significantly increase the risk of developing MF. In addition, patients with MF have a high risk 
of developing secondary tumours, both haematological and non-haematological, and this risk is 




















2.1. Extracellular microvesicles 
 
Among the possible mechanisms of inflammation development/propagation, it has been described 
that the contribution of extracellular microvesicles (EVs) is crucial. EVs, which are composed of 
microvesicles (MVs, 150-1000 nm) and exosomes (30-150 nm), are released by a wide variety of 
cells during homeostasis and cellular activation with pleiotropic effects on signalling between cells
(53). EVs express antigens and contain constituents from the source cell including microRNAs.
This mechanism supports cellular communication because, proteins, lipids and nucleic acids (DNA, 
miRNA, etc.) can be found within EVs with the potential to affect the short and long distance 
microenvironment. Therefore, they have the unique ability to transport membrane and cargo 
molecules between cells and quickly spread cellular information without the need for cell migration
(53, 54).    
The biogenesis of MVs occurs by extroflection of the cell membrane, which in turn, is made 
possible by the action of proteins and lipids that are able to modify the rigidity of the membrane 
itself. Subsequently, the detachment of the nascent vesicle from the plasma membrane takes place 
thanks to the actin-myosin contractile system and with ATP consumption. Their development is 
regulated by small GTPases from the ARF, Rab and Rho families. Contrary to MVs, the exosomes 
are released by the multivascular bodies of the cells (55). 
Peripheral blood contains MVs resulting from platelets/megakaryocytes, red blood cells, leukocytes 
and endothelial cells; however, platelet/megakaryocytes-derived MVs are the most abundant (56). 
Specifically, Flaumenhaft et al identified the circulating MVs of megakaryocyte and platelet origin. 
According to this study, the megakaryocyte MVs are CD41+/CD62P- and express 
phosphatidylserine on the surface. Furthermore, these MVs are characterized by the presence of 
Filamin A. The platelet MVs are instead CD41, CD62P and LAMP-1 positive (57).  
Numerous studies indicate that EVs, due to their cargo in lipids, inflammatory cytokines/proteins 
and nucleic acid, have pivotal role in the initiation, propagation and regulation of inflammatory 
diseases and might be used as biomarkers. They likely play a role in modulating inflammatory and 
autoimmune diseases, such as arthritis, diabetes and lupus. MVs enhance inflammation through 
secretion or surface expression of pro-inflammatory cytokines that promote an inflammatory 
microenvironment and drive immunomodulatory/immunosuppressive activities (58).  
Fitzgerald et al. have systematically analyzed the association between 33 cytokines and EVs in 
eight in vitro, ex vivo and in vivo biological systems (cultured T cells, cultured monocytes, explants 
of tonsillar, cervical, placental villous, and amnion tissues, amniotic fluid, and blood plasma of 
healthy volunteers).
They found that a cytokine could be released predominantly either in soluble or in EV-associated 
form depending on the biological system. These two systems are not strictly separated, as many 
cytokines in vitro, ex vivo, and in vivo are released in EV-encapsulated forms and can elicit
biological effects upon contact with sensitive cells. Moreover, upon stimulation, the pattern of 
encapsulation changes depending on the stimulus. This suggests that the encapsulation of cytokines 
in EVs is not simply the property of a particular cytokine, but rather a tight biological process that 
can be changed upon system activation. Such a targeting would require that EV-associated 
cytokines are biologically active, and they provided evidence of such activity. Their experiments 
demonstrated that the biological activity of the EV-encapsulated cytokines was the same whether 
they released the cytokines or provided them in EVs. 
Multiple biologic meanings have been suggested to loading EVs with cytokines: (1) could be a 
mechanism to dispose of products when they are over-produced and simultaneously protecting the
releasing cell from an autocrine effect; (2) EVs protect cytokines from environmental degradation. 
Indeed, EV-entrapped cytokines are protected from trypsin digestion; (3) may be a mechanism 
whereby the cytokine expressing cell could expand its sphere of influence to concentrate cytokines 
at the surface of other cells that might not otherwise be targeted by cytokines in solution (59). 
These studies show that deciphering the regulatory mechanisms of EV encapsulation could lead to a 
better understanding of cell-cell communications in health and disease. 
Based on the bidirectional transfer of molecules between tumour cells and the microenvironment, 
EVs are emerging players. Recent evidence suggests that EVs have crucial roles in cancer 
development, including pre-metastatic niche formation and metastasis, angiogenesis and 
suppression of the immune system. Cancer cells are now recognized to secrete more EVs than their 
non-malignant counterparts and EVs have strong potential as blood-based biomarkers for the 
diagnosis, prognostication and surveillance of cancer.  Thus, EVs play a key role in the regulation 
of immunity/inflammation and cancer, which in turn can contribute to the further release of EV (60, 
61). 
Few studies have shown elevated circulating EVs levels in patients with MPN (62, 63). 
Trappenburg et al have shown that patients with ET have higher number of circulating 
microparticles with platelet and endothelial markers, suggesting an ongoing platelet and endothelial 
activation and a role of microparticles in thrombosis of ET (64).  Furthermore, Timari et al found 
that EVs released by MSCs from patients with MPN were found to be selectively enriched in 
miR155, and they induced an increase in colony forming unit (CFU) ability of neoplastic CD34+ 
cells (65). However, the role of EVs in MPN, including MF, has yet to be addressed. A deepening 
of their role in MPNs would be useful to better understand the mechanisms underlying the disease 
and to identify new therapeutic strategies. 
 
3. Immune dysregulation in MF 
 
The survey of US Surveillance, Epidemiology, and End Results, (SEER)-Medicare database (1,017 
MPNs cases) has documented that autoimmune conditions, overall, are associated with an increased 
risk of MPN with respect to healthy controls. Autoimmune conditions can cause an immune-related 
and inflammation-driven tumorigenesis that may result in MPN. Furthermore, therapies given to 
patients with autoimmune disease (anti-inflammatory and immunosuppressive agents) can play a 
role in the risk of developing MPN. Moreover, there might be a shared common genetic and/or 
environmental susceptibility in autoimmune diseases and MPN (37).  
Several studies provided evidence that T, B, and NK cell lineages could be involved by the MPN 
mutations, suggesting that the target cell in MPN is a myelo-lymphoid progenitor. Anyway, the 
consequences of the involvement of B, T, and NK cells by the somatic mutation that drives the 
clonal proliferation are still unclear, but they could underline some of the immunologic 
abnormalities of MPN patients. 
Few studies analyzed lymphocyte subsets and their possible correlations with the 
immune/inflammatory features of MPNs. First of all, Cervantes et al have documented a reduced 
absolute circulating lymphocyte count in MF patients. Despite this, there was an increase of 
cytotoxic T cells (CD3+/ CD56+) in most of PMF patients and 10% of them showed an increased 
CD19+/CD5+ B cell subpopulation (66). 
In another study, the presence of the MPLW515K gene mutation in CD4+ lymphocytes was 
observed, suggesting that the lymphoid compartment may also be affected by the mutation (67). 
Regulatory T lymphocytes (Treg), which are a subpopulation of T helper lymphocytes with the role 
of maintaining immune tolerance, show altered number. Zhao et al investigated the
frequency/function of Tregs (CD4+CD25+ FOXP3+) in PV patients and healthy donors. Tregs were 
significantly increased in patients and the expression of FOXP3, the master regulator of the 
immunesuppressive activity of Tregs, was increased (37,68). Conversely, Keohane et al reported 
low levels of Tregs in 50 MPN patients as compared to healthy donors (69). It has also been 
observed that the mutational status can influence the proportion between the regulatory T 
lymphocyte subpopulations. If we consider the three regulatory T-subpopulations identified by 
Miyara et al, the "triple negative" MF patients show an increase in the circulating population I
(CD3+CCD4+ CCD45RA+ CD25+ CD127low); conversely, patients with the JAK2V617F
mutation show an increase in circulating population III (CD3+CD4+CD45RA-CD25 + CD127-)
(70). 
Regarding other subset of immune cells, dysregulations have also been observed in the 
monocyte/macrophage population. Thiele et al. have revealed an expansion of the 
monocyte/macrophage cell population in the bone marrow of PMF patients, with a significant 
increase in the number of mature CD68+ macrophages. These macrophages are also 
morphologically altered (71). Anyway, monocytosis in MPNs is a rare event, restricted to PMF, and 
is associated with rapid disease progression. Furthermore, it has been described that the monocytes 
of patients with PMF are hyperactivated, because there is an increased production of 
proinflammatory cytokines and transforming growth factor-beta (TGF-
mechanism (72).  
Myeloid-derived suppressor cells (MDSCs) is a subpopulation of immune cells that plays an 
important role in the immune system and tumorigenesis. This population is part of a larger and 
more complex group of cells that are fundamental for the mechanisms of immunological tolerance 
towards the tumor: they guarantee an immunosuppression that allows the neoplastic clone to 
progress undisturbed (37). MDSCs are part of a generalized circuit of immunosuppression in which 
other tolerogenic cells are active participants. It is not surprising, therefore, that in MPN the 
MDSCs (CD11b+CD14-CD33+) are significantly increased, as demonstrated by Kundra et al. (73).  
The network regulating the relationship between hematopoietic stem/progenitor cells and 
immunoregulatory cells has not been completely elucidated in MPN. There are many outstanding 
questions on the role of immunomodulation in the generation and progression of MPN that deserve 
to be addressed. For example, mesenchymal stem cells (MSCs) are key cells for immunoregulation 
and inflammation. MSCs are a key component of the hematopoietic niche, where they support the 
proliferation and differentiation of HSC. Furthermore, MSCs have a fundamental role in immune 
regulation, suppressing the proliferation of T cells and favoring the immunosuppressive function of 
regulatory T lymphocytes (Treg) (74). The bone marrow of MF patients has both cellular and 
extracellular changes due to inflammation/fibrosis that modifies the hematopoietic niche; for 
example, alterations of fibroblasts, osteoblasts, endothelial cells and even MSCs are found (75). 
The MF inflammatory microenvironment shows a high production of FGF and VEGF, which 
stimulate neo-angiogenesis and marrow fibrosis, and of PDGF and TGF- ce an 
increase in matrix proteins such as proteoglycans, fibronectin and collagen (76). Chronic 
inflammation therefore creates a microenvironment that facilitates the release of many molecules 
from the cells of the microenvironment and from the hemopoietic clone, that leads to an 
"inflammatory storm" in the bone marrow (75). Due to the overproduction of these factors, the 





Fig 14: The vicious circle that is created between cells and inflammatory microenvironment in the 




The concept of onco-inflammation" and immunoregulation in MPN offered further suggestions for 
therapeutic strategies. Approaches with anti-inflammatory/immunomodulatory drugs have been 
designed as promising drug therapies in MPN, including JAK1/2 inhibitors (such as Ruxolitinib), 








3.1.1 Monocytes physiology 
 
Monocytes are immune cells that are part of the reticuloendothelial system, which is a system 
playing a role of sentinel of the organism for protection from what is foreign. Monocytes are 
circulating cells that can be recruited from tissues and mature on macrophages. Alternatively, they 
can mature to dendritic cells (Monocyte derived DCs) (78). They derive from a common myeloid 
precursor and develop in the primary lymphoid organs (bone marrow in adults, liver in fetal life). 
Starting from this precursor, a factor called M-CSF (macrophage-colony stimulating factor) is 
essential for their terminal maturation. In the blood, mature monocytes account for about 5-10% of 











Although monocytes are generally referred to as circulating precursors of macrophages, today their 
role in the immune system has been expanded. Thanks to the characterization of surface antigens, in 
fact, it is possible to identify the various phases of their development and to distinguish the different 
subsets that are present in humans. 
In the murine model, circulating monocytes are LY6C + and lose this protein once activated and 
migrated into lymph nodes or tissues. In this second phase, there is also an increase in the 
transcriptional levels of IL-
LY6C monocytes control the tissue environment and are able to present a possible antigen to the T 
lymphocytes, even without differentiating to macrophages (78). 
In humans, LY6C + monocytes are defined as "classic" because they are the most represented 
population in the peripheral blood (80-90%). From the point of view of antigenic expression, 
classical monocytes are CD14 ++/CD16-. LY6C- monocytes, on the other hand, are defined as 
"non-classical" and are CD14+/CD16 ++. They can also be referred to as "patrolling subset"
because their role is to patrol the vessels, checking the integrity of the endothelium (82). More 
recently, a third class of monocytes has been identified: these are the "intermediate" monocytes, 
with characteristic antigenic CD14 ++/CD16+ expression. Although numerically smaller than the 
other subset, they are interesting because they are able to respond to the lipopolysaccharide (LPS)
stimulus by TNF- is the LPS 
receptor 83). 
In addition to the expression of CD14 and CD16, the three subsets can also be distinguished by the 
different secretory capacities. Following stimulation with LPS, it appears that: 
- Classic monocytes produce high levels and a wide variety of cytokines (G-CSF, IL-10, CCL2, IL-
6 TNF- -6) 
- Intermediate monocytes produce high levels of pro-inflammatory cytokines such as TNF- , 
and IL-6 
- Non-classical monocytes produce the same cytokines as the other subset, but generally they 
mainly produce anti-inflammatory cytokines (such as IL10).  
The same study also highlighted other differences regarding the phenotype of the three sub-sets: 
- CCR2, CXCR1, CXCR2 and CD62L are highly expressed by classical monocytes. 
- CD64, CCR1, CCR2, CX3CR1, CD11b, CD33 and CD115 are expressed at intermediate levels in 
intermediate monocytes; CD40, CD54 and HLA-DR are expressed instead in this subset at high 
levels. 




Fig 16: Phenotypic and biological characteristics of the three subsets of monocytes (85) 
 
Based on this information, each of the three sub-sets can be assigned a specific role. Classic 
monocytes are the first to be recruited and come out from the bone marrow to go into the 
bloodstream. They have high phagocytic capacity, thanks to the production of peroxidase and 
produce high levels of Reactive oxygen species (ROS), IL10, IL1- -
stimulated by LPS and they differentiate into intermediate and non-classical monocytes. They are 
involved in angiogenesis and coagulation. 
Intermediate monocytes, on the other hand, are typically inflammatory and have a reduced 
phagocytic capacity and peroxidase activity but produce higher levels of TNF- - -6 under 
inflammatory stimulus. From the bloodstream they reach the tissues and sites of inflammation by 
CX3CR1 and CCR5 receptors that mediate the accumulation of monocytes in inflammatory sites 
and that bind CCL3, expressed by macrophages in inflammatory sites, and CCL5 (RANTES), 
expressed and secreted by T cells to recruit leukocytes to the inflammatory sites. They are increased
in diseases associated to chronic inflammation. They also express CD40 for the activation of T 
lymphocytes. 
Non-classical monocytes patrol the vessels and from the bloodstream invade the tissues damaged by 
inflammation through the expression of CX3CR1, which is the receptor for chemokine CX3CL, and 
contribute to angiogenesis and fibrosis, favouring the production of collagen (IL-10 and TGF- -
relate). They are in fact defined as "patrolling". They therefore have an anti-inflammatory function. 
They can produce IL1- - se to nucleic acids (86). 
 
3.1.2 Monocytes and MF 
 
Previous studies have partially characterized the monocyte population in the course of MF. It has 
been shown that monocytes of patients with MPN are more functionally active and therefore 
produce large amounts of cytokines (TGF- -1 and substance P) (72);  
In 2016, a possible role of monocytes was shown in the development of one of the major clinical 
features of MF: marrow fibrosis. In fact, high percentages of a particular monocyte-derived cell 
type, namely fibrocyte, has been identified in patients with MF at the fibrotic stage (87). The 
monocyte-fibrocyte transition is mediated by the Pentraxin-3 (PTX3), released by macrophages and 
88). 
To carry out their task in the context of the immune system, monocytes are recalled at the site of 
inflammation thanks to some chemokines, including the most important Monocyte chemoattractant 
protein 1 (MCP-1). It has been recently described that a given polymorphism of MCP-1-2518A/G, 
may predispose to the development of MF. This polymorphism had already been associated with 
other pathological conditions (autoimmune disorders, atherosclerosis, chronic infections), which 
places monocytes at the centre of the etiopathogenesis of various immune defects (89). 
To investigate their role in MPN, monocyte lines with stable JAK2V617F mutation were developed.
They were then used as a study model and the levels of pro and anti-inflammatory factors were 
evaluated. The results show that the mutated cells produce a greater quantity of metalloproteases 
(and their inhibitors), growth factors and other crucial substances (such as PTX3) compared to 
"wild type" cells (90). 
In addition to being predictive of disease development and as study model for the underlying 
etiopathogenetic mechanisms, it was  tested whether monocytes could be a prognostic index for 
MF. In a recent study, patients were stratified based on absolute monocyte counts and it was shown 
that monocytosis is associated with a poorer prognosis (91). 
It has also been shown that monocytes are able to express the receptor for angiopoietin 2, namely
Tie-2, and therefore they can promote angiogenesis in an autocrine manner (92). In fact, patients 
with MF have an increased concentration of Tie-2+ monocytes in the peripheral blood. In this case 
we are dealing with monocytes of the "intermediate" subset (CD14 ++ CD16 +) (93).  
However, monocytes expressing the same receptor for angiopoietin 2 have also been identified in 
-classical monocytes (CD14 + CD16 ++) (94). This last 
evidence is very relevant, as an increased neo-
demonstrated (95). Monocytes therefore seem to be responsible for this phenomenon.  
It has also been shown that the expression of IL- could be associated with an 
increased risk of thrombosis in patients with MF who have the JAK2V617F mutation (96). 
Based on these observations, monocytes may have a leading role in the development and 
maintenance of MF. Nevertheless, additional studies are needed to understand the mechanisms 




















MF is still a treatment-orphan disease that may be cured only by allogeneic stem cell transplant in younger 
selected patients.  However, as above described, regardless of the type of mutation, patients with MF 
have hyperactivation of the JAK/STAT pathway. An effective therapeutic approach, therefore,
would be to inhibit the action of the JAK kinase. The first drug developed and approved for the 
treatment of patients with MF was Ruxolitinib (or INCB018424):  a JAK1 / 2 inhibitor (97). This 
drug was approved by the EMA in 2012 and is marketed under the trade name of JAKAVI (98). 
The approval of the drug came thanks to two main clinical studies: 
- COMFORT I: in which Ruxolitinib was compared with placebo (99) 
- COMFORT II: in which Ruxolitinib was compared with the best available therapy (100) 
Thanks to these two trials, Ruxolitinib has been approved for patients with intermediate (1-2) or 
high-risk MF who are not eligible for hematopoietic stem cell transplantation. 









Regarding the mechanism of action, Ruxolitinib is able to inhibit the kinase activity of JAK1/2 by 
binding to the ATP "binding domain" of the protein (the site where ATP normally resides). In 
particular, the Ruxolitinib molecule has a double ring system, through which it forms two hydrogen 





Fig 18: Molecular interaction between the JAK2 kinase and its inhibitor Ruxolitinib. (102) 
 
The binding to the ATP "binding domain" turns out to be effective in inhibiting the activity of 
JAK1/2, since the ATP is not only used by the kinase to obtain phosphate groups, but it also seems 
to have a role in stabilizing the pseudokinase domain in the absence of stimulus. Ruxolitinib, 
therefore, would act as an ATP mimetic, stabilizing the inhibited form of JAK1/2 (103).  
In these randomised controlled trials it has demonstrated efficacy in spleen volume reduction and 
symptom burden reduction with a moderate improvement in overall survival of PMF patients (104).
Despite these benefits, there is limited impact to induce complete haematological remission with 
normalisation of blood counts, reduce the mutant allele burden or reverse bone marrow fibrosis. 
Clonal evolution has been observed on ruxolitinib therapy and transformation to acute leukaemia 
can still occur. 
Spleen size reduction occurs in more than 50% of patients with MF and a significant reduction in 
constitutional symptoms is also observed. This can be related to the reduction of pro-inflammatory 
cytokines. Furthermore, this finding demonstrates how the inhibition of the JAK/STAT pathway 
has important anti-inflammatory implications (97). 
Although important therapeutic effects have been demonstrated following treatment with 
Ruxolitinib, numerous side effects have however been reported. These are due to the fact that the 
drug is not selective for the mutated kinase, and therefore also acts on the wild type form. The 
clinical study COMFORT I showed that neutropenia, urinary tract infections and herpes zoster were
observed in patients treated with Ruxolitinib (99). These evidences were confirmed following a 5-
year follow-up in the context of the clinical study COMFORT II, with an increased risk of 
developing pneumonia, sepsis and tuberculosis (100). Interestingly, new drugs are being studied 




Fig 19: Adverse effects observed in patients with MF treated with Ruxolitinib or with the best 
available therapy (100) 
 
 
The risk of infections is a serious problem for individuals with MF, as it represents about 10% of 
the causes of death for these patients. This is due to the profound deregulation of the immune 
system in these subjects, which affects both the cellular component and mediators such as cytokines 
(106). The question then arose of verifying whether treatment with Ruxolitinib could exacerbate 
this situation of immunodepression in treated patients, since the JAK/STAT pathway plays a key 
role in many immune-related processes. 
According to studies conducted both in vivo and in vitro on dendritic cells, Ruxolitinib is able to 
inhibit their differentiation capacity, the ability to produce IL-12, the migration and expression of 
activation markers (107). Dendritic cells are fundamental for the antigen presentation process to T 
cells and, moreover, are able to produce various cytokines (such as IL12, IL23), which in turn drive 
the Th1 and Th17 response. For this reason, reduced functionality of dendritic cells results in 
dysfunction of the immune system (108). 
The effects of Ruxolitinib on natural killer cells were also studied. Natural killer cells are effector 
cells with a critical role in defence against viral infections and cancer cells. They are able to 
produce IFN- - 108). In a recent study, an important reduction in the frequency of these 
cells were demonstrated in patients with MF treated with Ruxolitinib. This may probably be due to 
a defective maturation process. In vitro, a reduced capacity to produce cytokines and lytic activity 
typical of this cell type was then highlighted (109). 
Tregs are reduced in MF. In a recent study, it was observed that this decrease is even more 
pronounced in patients treated with Ruxolitinib. These authors have in fact demonstrated a 
reduction of CD4+CD127low CD25high FOXP3 + cells in the peripheral blood of patients. They 
also demonstrated, in vivo and in vitro, a functional block of these cells (110). 
 
 
Fig 20: Effects of Ruxolitinib on crucial cells of the immune system. (108). 
 
Of note, although monocytes are key players of the inflammatory microenvironment, in MF their 
pathogenetic role, both at baseline and following treatment with Ruxolitinib, is far from being 
defined. 
 
































This thesis is based on four projects aiming to address the 
pathogenetic role of the immune/inflammatory 
microenvironment in MF.  
 
Specific aims were: 
 
1. To analyze the role of inflammation on the functional behaviour of normal hemopoietic 
stem/progenitor CD34+ cells. It has been hypothesized that the sustained inflammatory 
microenvironment of MF can alter crucial biological processes, leading to genomic instability 
and cancer progression. To mirror the in vivo inflammatory microenvironment, here we 
investigated the in vitro functional effects and role of combined crucial proinflammatory 
cytokines (IL- - -6, and tissue inhibitor of metalloproteases (TIMP-1)) on the 
functional behaviour of normal CD34+ cells from  neonatal umbilical cord blood (CB) and adult 
normal G-CSF-mobilized peripheral blood (mPB) in the presence or absence of bone marrow 
MSCs. Specifically, we analysed the effects of these selected inflammatory mediators on the 
viability, proliferative activity, clonogenic potential and migration capability of CD34+ cells.
Results of these project have been published on Mediators Inflammation  2018 Jul 
4;2018:5974613. doi: 10.1155/2018/5974613. eCollection 2018 .  
 
2. To characterize the bio-molecular profile of circulating MVs in MPN and particularly MF. 
Circulating MVs, as biomarkers of disease/malignancy and as contributors of the inflammatory 
network in MPN, are an open question. Here we investigated: 1) the profile of MVs in MF and 
ET; 2) whether MVs proportions could be related to severity of disease; 3) the role of 
inflammation on MVs frequency in MF; 4) the effects of Ruxolitinib on MVs proportion in MF; 
4) the microRNA (miR) cargo of circulating MVs from MF patients. Results of these projects 
have been published on British Journal of Haematology , 2019 Jun;185(5):987-991. doi: 
10.1111/bjh.15682. Epub 2018 Nov 18  and presented to the following Congresses: American 
Society of Hematology (ASH) 2017: Blood 2017 130:4220; European Hematology Association 
(EHA) 2017: abstract n. E1309; XV Congress of the Italian Society of Experimental Hematology 
(SIES) Rimini, Italy, 18-20 October 2018, Haematologica Abstract n° PO047; American Society 
of Hematology (ASH) 2018: Blood 2018 132:4334; doi: https://doi.org/10.1182/blood-2018-99-
114507; 
 
3. To characterize the circulating immune microenvironment of MF. Infectious complications
are the leading cause of morbidity and mortality constituting more than 10% of all patient deaths.
In order to understand whether the infectious events are caused by deficits in the innate or
adaptive immune response, a comprehensive analysis of key immune cells is required. Based on
this background and considering the essential role of the JAK/STAT pathways in shaping the
immune response, we enumerated and functionally characterized key immune-cell subsets
including (dendritic cells (DCs), T-helper (Th) 17 cells , regulatory T cells (Tregs) and innate 
lymphoid cells (ILC)) with the aim to investigate their putative role in immunosurveillance in 
MF. Results of these project have been published on Oncoimmunology  2017 
Jul;6(10):e1345402. doi: 10.1080/2162402X.2017.1345402. eCollection 2017 . 
 
4. To investigate the role of circulating monocytes in the inflammatory microenvironment of
MF and to evaluate whether and to what extent Ruxolitinib may influence their in vitro / in
vivo behavior. Monocytes play a key role in the inflammatory microenvironment of MPN.  
Ruxolitinib improve the therapeutic scenario of MF by reducing splenomegaly and systemic 
symptoms in a significant fraction of patients. Nonetheless, Ruxolitinib is burdened by 
hematological and extra-hematological toxicity (i.e.: infections). The in vitro and ex vivo
inhibitory effects of Ruxolitinib on number/function of dendritic cells and T-cells (including 
Tregs) have been previously described. However, to date, in MF the effects of Ruxolitinib on 
monocytes biology have never been investigated. Based on this evidence and considering the 
essential role of the JAK/STAT pathways in shaping the immune response, the main purpose 
was: 1) to phenotypically and functionally characterize circulating monocytes in MF before and 
after 6 months of in vivo treatment with Ruxolitinib; 2) to address monocyte  interaction with the 
inflammatory microenvironment and 3) to investigate whether and at what extent Ruxolitinib
affects the in vitro/in vivo behaviour of circulating monocytes from MF patients. The driving 
hypothesis of the present proposal is that the analysis of the in vitro/in vivo biological effects of 
Ruxolitinib on the monocytes compartment will contribute to clarify the role of JAK1/2 
inhibition in the modulation of the immune landscape of MF. Results of these project have been 
submitted for publication Frontiers in Immunology" and presented to the following 
Congress European Hematology Association (EHA) Congress 2018: abstract n. PS1345.  
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Inflammation may play a role in cancer. However, the contribution of cytokine-mediated crosstalk 
between normal hemopoietic stem/progenitor cells (HSPCs) and their (inflammatory) 
microenvironment is largely elusive. Here we compared survival, phenotype, and function of 
neonatal (umbilical cord blood (CB)) and adult (normal G-CSF-mobilized peripheral blood (mPB))
CD34+ cells after in vitro exposure to combined crucial inflammatory factors such as interleukin-
(IL-) 1 , IL-6, tumor necrosis factor- (TNF-) , or tissue inhibitor of metalloproteinases-1 (TIMP-
1). To mimic bone marrow (BM) niche, coculture experiments with normal BM stromal cells 
(BMSCs) were also performed. We found that combined inflammatory cytokines increased only the 
in vitro survival of CB-derived CD34+ cells by reducing apoptosis. Conversely, selected 
combinations of inflammatory cytokines (IL-1 + TNF- , IL-6 + TNF- , and IL-1 + TNF- + 
TIMP-1) mainly enhanced the in vitro CXCR4- driven migration of mPB-derived CD34+ cells. 
TNF- , alone or in combination, upregulated CD44 and CD13 expression in both sources. Finally, 
BMSCs alone increased survival/migration of CB- and mPB-derived CD34+ cells at the same 
extent of the combined inflammatory cytokines; importantly, their copresence did not show 
additive/synergistic effect. Taken together, these data indicate that combined proinflammatory 























Hemopoietic stem/progenitor cell (HSPC) activation and retention are modulated by the 
bone marrow (BM) niche where they are located. In response to inflammation and/or BM injury, 
long-term quiescent hemopoietic stem cells (HSCs) are efficiently recruited into the cell cycle 
progression returning back to quiescence after reestablishment of homeostasis [1, 2]. Inflammation 
is a fundamental response that protects tissues from damage and preserves internal homeostasis.
However, chronic inflammation may hinder functionality of different tissues and has been 
suggested to cover a key role in cancer [3].  
Proinflammatory cytokines are emerging as key regulators of steady-state and infection-
driven hemopoiesis. Recent findings contributed to highlight how HSPC fate could be dictated by 
inflammatory factors in the BM microenvironment as HSPCs may actively respond to danger 
signals and proinflammatory cytokines [4, 5]. However, excessive chronic signalling can have 
negative effects on HSPC regulation and function [6]. Moreover, abnormalities in the inflammatory
signalling pathways have been discovered in both preleukemic and leukemic diseases [7]. BM 
mesenchymal stromal cells (BMSCs) are one of the most important components of the BM 
microenvironment. They respond to various microenvironment stimuli by changing their secretory 
capacity and displaying immune-suppressive activity through direct or indirect production of 
prostaglandin E-2, indoleamine 2,3-dioxygenase, interleukin- (IL-) 10 [8 10], and soluble receptors 
for IL-1 and tumor necrosis factor- -
stromal cells may also create a proinflammatory environment that promotes malignant 
transformation and disease progression [12]. In such process, several factors and pathways have 
been implicated but it is not clear how inflammation could affect or transform HSPCs. 
Understanding the direct cellular target(s) of proinflammatory cytokines is a critical step to better 
clarifying how HSCs/HSPCs are regulated in the BM niche.  
Granulocyte colony-stimulating factor- (G-CSF-) mobilized peripheral blood (mPB) and 
umbilical cord blood (CB) are two of the current sources of HSPCs for transplantation in 
hematological malignancies [13]; however, insights into the effects mediated by inflammation on 
neonatal and adult HSPCs are still elusive. In the last years, several phenotypic and functional 
differences between CB and mPB-derived HSPCs have been described [14 19]. However, so far, 
studies analysing the adaptations of HSPCs from these two sources to inflammatory cytokines were 
focused on a limited number of cytokines which were individually tested [20 24].  
To mirror the in vivo inflammatory microenvironment, here we investigated the role of 
combined crucial proinflammatory cytokines (IL- - -6, and tissue inhibitor of 
metalloproteases (TIMP-1)) on the in vitro functional behavior of CB- or mPB-derived CD34+ cells 


























1. Selected Combinations of Proinflammatory Cytokines Promote the In Vitro Survival of CB-
Derived CD34+ Cells. 
To test the role of proinflammatory factors on HSPCs, we firstly evaluated the in vitro 
survival of CB- and mPB derived CD34+ cells in the presence of IL-6, IL- - -1, 
at concentrations previously shown by us to be effective in dose-response experiments [20]. 
Spontaneous survival rate of CB-derived CD34+ cells was higher as compared to mPB 
.05; Figures 1(a) and 1(b)).  
As shown in Figure S1, CB-derived CD34+ cell survival was further enhanced by TIMP-1, 
IL- -  Compared to 
untreated cells (control), TIMP-1, IL- -6 alone poorly promoted the survival of mPB- and 
CB derived CD34+ cells with the notable exception of TNF-  .05) 
increased mPB-derived CD34+ cell survival.Therefore, based on these results and on data reported 
in literature [20, 25, 27], we hypothesized that combinations of cytokines can make CB- or mPB-
derived CD34+ cells more responsive to inflammatory stimuli. As shown in Figure 1(a), when 
cytokines were two-by-two combined, we found that IL- - .01), IL-6 + IL-
0.05), or TNF- .01) or TIMP- .01) significantly increased the percentage of viable 
CB-derived CD34+ cells as compared with the untreated counterparts. In contrast, only IL-
- - .001).  
Testing multiple cytokine combinations (Figure 1(b)), the survival of CB-derived and mPB-
derived CD34+ cells was significantly increased in the presence of IL- - -
0. .001, resp.) as compared with untreated cells. When we compared CB and mPB 
(Figures 1(a) and 1(b)), the survival rate of CB-derived CD34+ cells was promoted in the presence 
of IL- -1 and IL-6 + TNF- .05).  
These data suggest that CD34+ cells from CB are more actively responsive to inflammatory 
cues than their mPB counterparts; however, multiple combinations are required to promote their 
survival.  
Subsequently, we examined whether a combination of proinflammatory factors would 
trigger CD34+ progenitor cell differentiation. In selected experiments, freshly isolated CD34+ cells 
were cultured in RPMI medium supplemented with or without additional proinflammatory factors 
for 24 hours. The expression of selected myeloid-specific markers (CD11c, CD13, CD14, and 
CD45) along with HSPC markers (CD38, CD133) or specific marker for cell adhesion/proliferation 
(CD44) was analyzed by flow cytometry. The expression of CD11c, CD14, CD38, CD45, and 
CD133 was not significantly affected by inflammatory factor treatment (data not shown). By 
contrast, after treatment with combined inflammatory cytokines, mPB- and CB-derived CD34+ 
cells upregulated the expression of CD13 and CD44 (Figures 1(c) and 1(d) and Supplementary 
Table 2). After treatment with IL-6 + IL- - -1, CB-derived CD34+ cells showed a 
5-fold increase in geometric mean fluorescence intensity (gMFI) of CD13 as compared to untreated 
.001). Accordingly, a statistically significant difference was also found in the 
presence of IL- -  or IL-6 + TNF- - - and 4.64- .001, resp.). 
A similar pattern was also found when mPB CD34+ cells were tested (Figure 1(c)).  
Consistent with CD13 expression, the combination of IL- - .01) and IL-6 + 
IL- - .05) ± TIMP- .01) induced a significantly higher CD44 expression in 
CB-derived CD34+ cells (>2-fold increase, respectively; Figure 1(d)). When we evaluated the 
mPB-derived CD34+ cells, CD44 expression markedly increased in the presence of IL- -
.001), IL-6 + TNF- .01), and the combination of cytokines .001). 
Importantly, TNF-
.001). 
Taken together, these results demonstrate that selected combinations of inflammatory 
cytokines, along with the promotion of the survival of CB-derived CD34+ cells, stimulate the 





Figure 1: Survival and phenotype of CD34+ cells from CB or mPB in the presence of combined 
proinflammatory cytokines. (a) Percentage of live CD34+ cells from CB (indicated as negative for Annexin 
V and PI (black columns, n=9) or mPB (grey columns, n=8) in vitro treated for 24 hours with a two-by-two-
factor combination and assessed using Annexin V/PI staining, as described in Methods. (b) Percentage of 
live CD34+ cells in the presence of multiple combinations of proinflammatory cytokines. (c d) Box-plot 
graphs with fold change of gMFI for CD13 and CD44 expression in CD34+ cells after treatment with 
different combinations of inflammatory cytokines. Dot lines were used to mark control samples without any 
treatment. All data are presented as mean ± SEM of n (as above described) experiments performed in 








2. Proinflammatory Cytokines Poorly Stimulate the Clonogenic Output of CD34+ Cells from 
CB and mPB.  
To confirm the capacity of selected proinflammatory cytokines to drive the HSPCs toward a 
myeloid lineage, we performed clonogenic assay.  
We therefore evaluated the CFU-C growth in the presence of proinflammatory factors in a 
two-by-two combination. As shown in Figure 2(a) and Supplementary Table 3, CFU-C growth from 
CB or mPB-derived CD34+ cells was not significantly affected by incubation with the 
proinflammatory cytokines as compared with untreated cells. When we used multiple combinations 
of cytokines (Figure 2(b)), we found an increased clonogenic output in the presence of IL- -
-1 for CB-derived CD34+ cells and in the presence of IL-6 + IL- -1 for the mPB 
.05, resp). Comparing the two sources, IL- - -1 led to an increase 
in the clonogenic output of CB-derived .05).  
Of note, when colony composition was analyzed, no significant difference was observed in 
the CFU-GM growth (Figures 2(c) and 2(d)) between treated and untreated cells with the notable 
exception of IL-6 + TIMP-1 for mPB-der .01). Moreover, comparing the 
two sources, the CFU-GM growth of the mPB-derived CD34+ cells was significantly enhanced by 
IL-6 + TNF- .05). As regards the erythroid lineage (Figures 2(e) and 2(f)), only IL-
TNF- -1 significantly promoted the BFU-E growth of CB CD34+ cells as compared to 
. .05, resp.). Interestingly, in the presence 
of IL-6 + TNF- - -E growth of mPB 
.05). Of note, IL-6 + TNF-
on the erythroid and granulomonocyte progenitors of mPB-derived CD34+ cells by enhancing
CFU-GM (Figure 2(c)) and inhibiting BFU-E growth (Figure 2(e)).  
To further investigate, we next examined the subtype compartment of CFU-GM and BFU-E 
as percentage of total CFU (Figure S3). As shown in Figure S3(A) and (B), we found that, after 
treatment with IL-6 + TNF- - -1, the CFU-GM growth of CB CD34+ cells was 
.05, 
resp.), whereas it decreased in the presence of IL- - - .05). No 
significant effects were observed when mPB CD34+ cells (Figure S3(C) and (D)) were analyzed.  
These findings demonstrate that inflammatory cytokines slightly stimulate the hemopoietic 





Figure 2: Clonogenic output of CB- and mPB-derived CD34+ cells after combined inflammatory stimuli 
treatment. Comparison of CFU-C formation between CB- (n=9 independent experiments) and mPB-derived 
(n=10 independent experiments) CD34+ cells cultured for 14 days in methylcellulose-based medium is 
shown. The total CFU-C output was assessed in the presence of inflammatory cytokines with the two-by-two 
combination (a) or multiple combinations (b). The CFU-GM (c d) and BFU-E (e f) output was assessed. 
The results are expressed as growth fold change of inflammatory cytokine-treated versus untreated cells 
(control). Control samples were marked with a dot line. All data are presented as mean ± SEM ( .05, 
. .05 CB versus mPB). 
 
3. Selected Combinations of Inflammatory Cytokines Mainly Enhance the In Vitro Migration 
of mPB-Derived CD34+ Cells. 
It has been reported that CXCL12 is chemotactic for CD34+ cells and that the migratory 
behavior of CD34+ cells depends on their source of origin [28].  
We firstly evaluated CXCR4 expression in CB- and mPBCD34+ cells. As shown in Figure 
3(a), the absolute number of CD34+ cells co-expressing CXCR4 was significantly increased in 
mPB .01). Accordingly, we observed a slight increase 
in the geometric mean value of CXCR4 in mPB CD34+ cells as compared to CB-derived CD34+ 
cells (Figures 3(b) and 3(c)).  
Subsequently, we compared spontaneous versus CXCL12- driven migration and no 
significant differences were found in the migration rate when CXCL12 was added in culture 
(Figures 3(d) and 3(e)). This was probably due to the fact that, to highlight the effects of the 
inflammatory cytokines, low CXCL12 dose (120 ng/mL) was used.  
To study the role of proinflammatory cytokines in the modulation of spontaneous or 
CXCL12-mediated migration, we set up the in vitro migration of CB- or mPB-derived CD34+ cells 
in the presence of CXCL12 alone or CXCL12 plus selected combinations of proinflammatory 
cytokines (Figures 3(d) and 3(e)). As compared to the spontaneous migration, CD34+ cells from 
mPB showed increased migration ability toward CXCL12 when IL- - -6 + TNF-
0.05, resp.), and IL- - MP-1 or IL-6 + TNF- - .01, resp.) were added. 
IL-6 + TNF- -1 ± IL-
0.01, resp.). As compared to migration toward CXCL12 alone, only IL- - -6 + TNF-
antly enhanced the migration of mPB- . .01, resp.). 
The migratory capacity toward CXCL12 of CB CD34+ cells was promoted only by IL-6+TNF-
-1 +IL- .05). Comparing the two sources, the migration rate of CD34+ cells from 
mPB was significantly enhanced when CXCL12 + IL- - - .05, resp.) and 
CXCL12 + IL-6 + TNF- .05) were added to the lower transwell chamber. These results 
demonstrate the capacity of selected combinations of inflammatory cytokines to increase the 
CXCR4-driven migration of CD34+ cells from mPB and CB. This effect was more prominent when 
mPB cells were assayed. 
 
 
Figure 3: Migratory response of CB- and mPB-derived CD34+ cells in the presence of combined 
inflammatory stimuli. (a) The absolute number of circulating CD34+ cells from CB unit (n=9) or mPB 
(n=5) and coexpressing the CXCR4 receptor are shown. (b) Representative histogram of CXCR4 expression 
in CB- and mPB-derived CD34+ cells compared to isotype control. (c) Geometric mean value of CXCR4-
positive cells on the CD34+ population after isolation from CB (n=5) and mPB (n=5) units. (d) Migration 
assay using transwell after o/n spontaneous migration (control) or exposure to CXCL12 (120 ng/mL) or to 
two-by-two inflammatory cytokines plus CXCL12 as chemoattractants. Percentages of migrated CD34+ 
cells from CB (black columns, n = 4) or mPB (grey columns, n = 4) are shown. (e) Migration assay using 
transwell after o/n spontaneous migration (control) or exposure to CXCL12 (120 ng/mL) or to CXCL12 plus 
multiple inflammatory cytokines as chemoattractants. Percentages of migrated CD34+ cells from CB (black 
columns, n = 4) or mPB (grey columns, n = 4) are shown. Data are presented as mean ± SEM of n (as above 
described) independent experiments (
 
 
4. CD34+ Cells from mPB Show Increased Clonogenic Ability after In Vitro Migration 
toward Selected Combinations of Proinflammatory Cytokines.  
Cell migration could be considered a selection of cells with different function and 
properties; for this reason, we tested the clonogenic potential of migrated CB and mPB CD34+ cells 
(Figure 2 and Supplementary Table 4). Of note, at variance with the results of freshly isolated cells 
(Figure 2) in terms of clonogenic output, CXCL12 + IL-6 + TNF-
TIMP-  
0.01) selected a subset of CD34+ cells from mPB with higher clonogenic potential as compared 
with CXCL12 alone (Figure 4(a). By contrast, no effects were found in the CB-derived counterparts 
(Figures 4(a) and 4(b)). Comparing the two sources, only the mPB-derived CD34+ cells migrated 
toward CXCL12 + IL-6 + TNF- - .05) (Figures 4(a) and 4(b)). 
We then analyzed separately CFU-GM (Figures 4(c) and 4(d)) and BFU-E (Figures 4(e) and 4(f)) 
growth, observing a significant promotion of the CFU-GM growth in mPB CD34+ cells after 
migration toward CXCL12 + IL-6 + TNF- -6 + IL- F- -1 as 
compared to 
-GM 
growth was higher after migration of mPB CD34+ cells toward CXCL12 + IL-6 + TNF-
(Figure 4(c)). With regard the erythroid progenitors, no significant differences in BFU-E growth 
were observed between treated and untreated cells of either CB or mPB, with exception of the 
migrated mPB-  Figures 4(e) and 
4(f)). Comparing the two sources, mPB .05)
after migration toward CXCL12 + IL-6 + TNF-  composition was analyzed (Figure 
S4), combined inflammatory factors do not significantly modify the CFU-GM/BFU-E proportion of 
migrated CD34+ cells of both sources. Overall, here we demonstrate that selected combinations of 
proinflammatory cytokines promoted the CXCR4-driven migration of mPB-derived CD34+ cells
with higher clonogenic ability and granulomonocytic potential.  
 
Figure 4: Clonogenic output of CB- or mPB-derived CD34+ cells after migration toward different 
combinations of inflammatory cytokines plus CXCL12. Panels a and b show the fold change of clonogenic 
potential of CB-derived (n=4 8 independent experiments) and mPB-derived CD34+ cells (n=4 9 
independent experiments) after migration toward CXCL12 with or without the two-by-two combination (a) 
or multiple (b) combinations of proinflammatory factors (postmigration CFU-C). (c d) Fold change of 
CFU-GM (c d) and BFU-E (e f) growth after migration towards CXCL12 in the presence of various 
combinations of cytokines. Dot lines were used to mark control samples after migration towards CXCL12. 
 
 
5. The Copresence of BMSCs and Combined Inflammatory Cytokines Does Not Show 
Additive/Synergistic Effect in Terms of Hemopoietic Supportive Role.  
To mimic the in vivo niche and to investigate the role of normal BMSCs in the 
inflammation-driven functional behaviour of normal HSPCs, we cocultured CB- or mPB-derived 
CD34+ cells with 
BMSCs from HD in the presence or absence of combined proinflammatory cytokines.  
As shown in Figure 5(a), the survival of CD34+ cells, either from CB or mPB, was 
significantly promoted by . .05, resp.). Interestingly, cocultures with 
BMSCs decreased the percentage of apoptotic CB CD34+ cells compared with the monoculture 
counterparts, 
0.05, data not shown). Similar results were obtained when cocultures of mPB CD34+ cells were 
0.05) (data not shown). However, in the presence of BMSCs (Figures 5(b) and 5(c)), the viability of 
cocultured CD34+ cells from CB or mPB was not significantly modified by the combined 
inflammatory factors as compared with the untreated counterparts. Comparing the two sources, only 
IL-6 + TIMP- .01) significantly increased the number of viable cocultured CB-derived 
CD34+ cells.  
Altogether, these findings demonstrate that (1) the survival of normal CD34+ cells is highly 
promoted by normal BMSCs through a strong protection from apoptosis, (2) BMSCs alone or the 
combined proinflammatory cytokines stimulate the survival of normal HSPCs at the same extent, 
and (3) the copresence of BMSCs and the combined inflammatory cytokines does not show 




Figure 5: Survival of CB- and mPB-derived CD34+ cells after cocultures with HD-BMSCs and in the 
presence or the absence of combined inflammatory cytokines. (a) Comparison between 24-hour 
monocultures and cocultures of CB and mPB-derived CD34+ cells (n=4 independent experiments, resp.) 
with BMSCs for in vitro survival (Annexin V/PI staining) is shown. Percentages of live CB- or mPB-CD34+ 
cells in the presence of BMSCs and/or proinflammatory cytokines with two by two combination (b) or 
multiple combinations (c) in comparison to CD34+ cells cocultured with BMSCs but without inflammatory 
stimuli are shown. For each graph, to highlight the comparison with cocultures, a dot line represented the 










6. Proinflammatory Cytokines Do Not Modify the In Vitro Migration of CD34+ Cells from CB and 
mPB toward BMSCs.  
The BMSCs produce CXCL12 as mediator of migratory response of different cell types. CXCL12 
is constitutively expressed by murine and human BM stromal cells [29]. To explore the effects of 
inflammation on the CXCR4-driven migratory ability of CD34+ cells in the presence or absence of 
BMSCs, we set up a migratory assay towards CXCL12 alone and BMSCs alone or in combination 
with various inflammatory cytokines. Of note, in order to mimic the in vivo pattern, along with 
inflammatory cytokines, a suboptimal concentration of CXCL12 (120 ng/mL) was also added.  
As shown in Figure 6(a), we compared the spontaneous migration of CD34+ cells from CB 
and mPB with the migration towards BMSCs seeded on the bottom of the transwell system, as 
chemoattractant. We found that the migration of CD34+ cells from both sources was promoted by 
BMSCs
CD34+ cells was not increased by the presence of CXCL12 + BMSCs as compared with that of 
CXCL12 alone or BMSCs alone (Figures 6(b) and 6(c)). When we added various combinations of 
proinflammatory cytokines in the presence of CXCL12 and BMSCs, once again we did not find any 
significant difference in the migration rate of CD34+ cells between treated and untreated cells or 
between the two sources (Figures 6(b) and 6(c)).  
These experiments demonstrate that the BMSCs exert a potent chemo attractive effect on 
normal HSPCs; moreover, in the presence of BMSCs, these combined proinflammatory factors are 




Figure 6: Migration of CB- and mPB-derived CD34+ cells towards CXCL12 and combined 
proinflammatory stimuli gradient and in the presence of normal BMSCs as further chemoattractant.  
(a) Comparison between spontaneous migration and migration toward BMSCs precultured on the bottom for 
24 hours before seeding CD34+ cells on the top of the transwell system (n=4 independent experiments, 
resp). Percentages of migrated CD34+ cells (seeded on the top of transwell) towards BMSCs (seeded 24 
hours before on the bottom) plus CXCL12 and proinflammatory cytokines (two-by-two combination (b) or 
multiple combinations (c)) as chemoattractant are shown. For each graph, to highlight the comparison with 
cocultures, a dot line represented the mean percentage of migrated cells towards CXCL12 in all 










Several cytokine-based strategies enhancing hemopoiesis, homing, and subsequent engraftment of 
CB/mPB-derived HSCs have been previously described [30]. However, critical steps are involved 
in these processes and further insights are necessary to better understand HSPCs homing and 
engraftment [31]. Along with a role as activators of immune cell function, a growing evidence now 
demonstrates that proinflammatory cytokines strongly affect the size and lineage distribution of the 
blood cells via reprogramming of HSC/HSPC and the supporting BM niche [5, 32]. Along with the 
cytokine storm, the network created by danger associated molecular patterns (PAMPs/DAMPs) and 
alarmins could deviate HSCs fate, directly or indirectly via stromal cells [33]. Based on these 
evidences and due to the lack of informative data, it is of utmost importance to clarify the impact of 
proinflammatory cytokines on the biology of the normal HSPC and its BM microenvironment. A 
better understanding of the mechanisms driven by the inflammatory milieu in HSPCs may lead to 
better transplantation outcomes and knowledge of hematological defects or malignancies.  
Here we tested various combinations of proinflammatory cytokines such as IL- -6, 
TNF- -1 in order to investigate their functional role on the in vitro behavior of young 
(CB-derived) and adult (mPB-derived) CD34+ cells. To mirror the in vivo condition, tested 
cytokines were two to two or multiple combined. We selected these inflammatory cytokines for the 
following features: (i) IL-6 is a pleiotropic proinflammatory cytokine that acts on many cell types 
including hemopoietic cells. It has been implicated as a critical activator of myelopoiesis in 
response to pathogen infection and chronic inflammation [34]; (ii) IL-
cytokine that mediates leukocytosis and thrombocytosis under inflammatory conditions by inducing 
various cytokines (i.e., granulocyte colony-stimulating factor and IL-6) [7]. Moreover, Pietras et al. 
[35] recently demonstrated that while IL- -state hemopoiesis, acute 
exposure to IL-  priming for a myeloid fate. 
Lastly, it is involved in the pathogenesis of solid tumors and hematological malignancies [36]; (iii) 
TNF- -renewal of HSPCs [37]. However, other 
evidence suggests that TNF signalling may enhance HSC function [38, 39]; (iiii) TIMP-1, through 
receptor (CD63) binding, has a role in multiple biological processes, including inflammation and 
immune regulation. We recently demonstrated that it displays cytokine-like features in the normal 
and leukemic HSPC compartment [25, 26].  
In addition, experimental evidence demonstrated that combined proinflammatory cytokines 
such as IL-6 and TNF-
NF-  other inflammatory cytokines and pathways (such as IL-6) are 
induced by IL-  Thus, the combined action of these 
cytokines could constitute a central signalling pathway that promotes inflammation and tumor 
growth.  
Comparing the two sources (neonatal versus adult) of HSPCs, here we demonstrated that the 
following:  
(1) Various combinations of inflammatory cytokines mainly enhance the in vitro survival of 
CB-derived CD34+ cells.  
(2) As compared to CB, mPB-derived CD34+ cells are susceptible to selected combinations of 
inflammatory factors in terms of proliferation and hemopoietic function.  
(3) TNF-
CD44, an adhesion/proliferation marker of normal and leukemic cells.  
(4) Along with an increased number of circulating CXCR4+CD34+ cells, selected combinations 
of inflammatory cytokines mainly enhance the in vitro migration of mPB-derived CD34+ 
cells.  
(5) BMSCs alone or combined inflammatory cytokines promote survival/migration of HSPCs 
from both sources at the same extent; moreover, their copresence does not show 
additive/synergistic effect in terms of hemopoietic supportive role.  
Of note, despite that the use of frozen/thawed CD34+ cells in some cases might have 
influenced the variability of phenotype/clonogenic ability, our results clearly demonstrate that the 
selected network of proinflammatory factors has the potential to activate either neonatal or adult 
normal hemopoiesis and acts as regulator of HSPCs. Moreover, these results are consistent with 
previously described promoting effects of the inflammatory microenvironment on hemopoiesis 
[4,7,12,]. Taking into account that the functional consequences of inflammation-related molecules 
depend on the duration of exposure (acute versus chronic), our results may provide a starting point 
to investigate whether the inflammatory cues contribute to creating a favorable milieu for the 
development of hematological malignancies through hemopoietic activation.  
Several groups evaluated the expression of hematopoietic markers, identifying various 
subpopulations of CD34+ cells in CB or mPB samples [41, 42]. Interestingly, we found that, when 
CB- or mPB-derived CD34+ cells were treated with combined proinflammatory cytokines including 
TNF-
various cell types, including myeloid hematopoietic cells, and regulates biological phenomena such 
as differentiation, proliferation, apoptosis, motility, and tumor cell invasion. Importantly, CD13 
degrades the chemokine CXCL11 and modulates CXCL12-induced migration [43, 44]. It has also 
been reported that high levels of human CD13 correlate with leukemic cell resistance to apoptosis 
[45]. Moreover, CD13 is differentially expressed in discrete states of differentiation of neoplastic 
myeloid cells [46]. Along with CD13, here we found modulation of the homing associated cell 
adhesion molecule CD44. Recently, CD44, as a receptor for hyaluronan, emerges as mediator of 
cell-cell and cell-matrix interactions and as pivotal trigger in cancer stem cell communication with 
their microenvironment [47, 48]. Here we identified combined proinflammatory cytokines including 
TNF-
Although TNF- -driven modulation of CD44 expression was already reportedin several cancers 
[49], this is the first time that a strong link has been found between combined inflammatory 
cytokines clearly indicate that the inflammation-driven CD13 and CD44 upregulation on neonatal 
or adult CD34+ cells has the potential of modulating key functional pathways (i.e., 
survival/differentiation) of the normal hemopoietic progenitor cells. Interestingly, these pathways 
may also play a role in myeloproliferation and leukemogenesis.  
Several studies have shown that HSC can be expanded in cytokine-driven culture and by 
MSC feed layers [50, 51]. Consistently, our data clearly showed that normal BMSCs enhance 
survival and migration of CB- and mPB-derived CD34+ cells. Due to their capacity to modulate 
oxidative stress, it is likely that BMSCs are capable of inhibiting apoptosis; moreover, producing 
CXCL12 [52], they enhance cell migration. Interestingly, even though it is likely that different 
mechanisms are involved, the BMSC-driven promoting effect of the CB-derived CD34+ cell 
survival is similar to that induced by the combined inflammatory cytokines. A similar trend was 
observed in mPB. However, for the first time, we investigated the copresence of BMSCs and 
various combinations of selected proinflammatory cytokines. Surprisingly, the copresence of 
inflammatory stimuli with BMSCs did not significantly modify the survival-migration rate of 
normal HSPCs as compared with that observed after stimulation with BMSCs alone or combined 
inflammatory cytokines alone. Of note, the BMSCs are capable to sustain the survival of mPB-
derived CD34+ cells in the presence of IL- -1. These findings demonstrate that in our 
culture system an acute inflammatory stimulus does not impair the hemopoietic-supportive role of 
BMSCs. Interestingly, based on murine models, it has been previously demonstrated that MSCs can 
modulate inflammation by secreting soluble receptors for IL-1 and TNF, which bind to IL-1 and 
TNF-  and neutralize the activity of the cytokines [53 55]. We can therefore hypothesize that in 
our cocultures the promotion of normal HSPCs survival/migration is mainly due to BMSCs which 
show regulatory properties of the hemopoietic function of HSPCs because they are capable of 
balancing the proinflammatory signal-driven hemopoietic activation. These results suggest that 
exploiting or modulating the thin balance between pro- and anti-inflammatory pathways may be a 





The goal of this study is the demonstration that an inflammatory microenvironment 
promotes distinct in vitro functional activation of neonatal and adult HSPCs and that an acute 
inflammatory stress does not impair the hemopoietic promoting effect of BMSCs. Moreover, this 
study may represent a starting point for future studies aiming at addressing the role of inflammation 
and the balance with anti-inflammatory signals in the functional behavior of normal HSPCs and 






















MATERIALS and METHODS  
Sample Collection 
CB samples (n=14) from normal fullterm deliveries were provided by the Cord Blood Bank of the 
University Hospital of Bologna after written informed consent. mPB samples (n=14) were obtained 
from hemopoietic stem cell transplantation donors. This study was approved by the medical Ethical 
Committee of the University Hospital of Bologna and was conducted in accordance with the 
Declaration of Helsinki. 
 
Cell Isolation 
Mononuclear cells (MNCs) were separated from CB and mPB samples (maximum after 1 day from 
harvesting) by stratification on Lympholyte-H 1.077 g/cm3 gradient (Gibco-Invitrogen, Milan, 
Italy), followed by red blood cell lysis for 15 min at 4°C. MNCs were then processed on magnetic 
columns for CD34+ cell isolation (mean purity 94 ± 4%) (CD34 Isolation kit; Miltenyi Biotec,
Bologna, Italy), as previously described [25], and treated with our combination of cytokines on the 
same day. In selected cases, CD34+ cells from CB or mPB were cryopreserved in liquid nitrogen 
and then thawed before testing with the combined inflammatory cytokines. Of note, to minimize the 
influence of freezing/thawing, only thawed CD34+ cells with a survival rate > 80% were used and 
the thawed CB/mPB cells were studied in the same experiment.  
 
Phenotype of Circulating CD34+ Cells 
The phenotype of circulating CD34+ cells was evaluated in CB and mPB samples by conventional 
flow cytometry, as previously described [20]. Antibodies used to characterize the CD34+ cells are 
listed in Supplementary Table 1. A minimum of 1 × 104 CD34+ cells were acquired by a BD Accuri 
C6 flow cytometer (Becton Dickinson, Milan, Italy). Analysis was performed excluding cellular 
debris in a SSC/FSC dot plot. The percentage of positive cells was calculated subtracting the value 
of the appropriate isotype controls. The absolute number 





Freshly isolated CD34+ cells (2 5 × 105) from CB units or mPB samples were maintained in RPMI 
1640 with 10% fetal bovine serum (FBS), with or without IL-6 (10 ng/mL), IL- -
-1 (100 ng/mL), alone or in different combinations (all from Thermo 
Scientific, Rockford, IL, USA). After 24 hours, cells were stained for 15 min at RT with Annexin-
VFLUOS Staining Kit (Roche, Penzberg, Germany). Samples were then immediately analyzed by a 
BD Accuri C6 flow cytometer. Results are expressed as percentage of live cells compared to the 
whole cells. 
 
Erythroid and Granulocytic Progenitor Assays  
CB/ mPB-derived CD34+ cells were cultured in vitro to achieve hematopoietic cell differentiation 
and the formation of colony-forming units (CFU-Cs), which is the sum of colony forming unit-
granulocyte macrophage (CFU-GM) and erythroid burst-forming units (BFU-E). Specifically, 
CD34+ cells were seeded in methylcellulose-based medium (human Stem- MACS HSC-CFU lite 
w/ Epo, Miltenyi Biotech) at 5 × 102 cells/mL in 35mm Petri dishes in the presence or absence of 
the selected proinflammatory factors: IL-6 (10 ng/mL), IL- ), TNF-
TIMP-1 (100 ng/ mL), alone or in combination. After 2 weeks of incubation at 37°C in 5% 
humidified CO2 atmosphere, CFU-C growth was evaluated by standard morphologic criteria using 
an inverted microscope (Axiovert 40, Zeiss, Milan, Italy). 
 
Migration Assay 
Migration of CB/mPB-purified CD34+ cells was assayed in transwell chambers (diameter 6.5 mm,
 [25]. In order to highlight the effects of 
the selected inflammatory cytokines, suboptimal CXCL12 gradient (120 ng/mL) was employed. 
 FBS containing 0.5 × 105 cells was added to the upper 
chamber -6 (10 ng/mL), IL-
TNF-  TIMP-1 (100 ng/mL) (alone or in combination) was added to the bottom 
chamber. After overnight incubation at 37°C in 5% humidified CO2 atmosphere, inserts (upper 
chambers) were removed and cells transmigrated into the lower chamber were recovered and 
counted by the Trypan Blue exclusion test. The amount of migrated cells was expressed as a
percentage of the input, applying the following formula: (number of migrated cells recovered from 
the lower compartment/total number of cells loaded in the upper compartment) × 100. In addition, 
migrated cells were assayed in methylcellulose-based medium for their ability to form 
hematopoietic colonies (as above described). 
 
Isolation and Expansion of Mesenchymal Stromal Cells (BMSCs) from Healthy 
Donors (HD) 
BMSCs were obtained from BM aspirates collected from HD (n = 3), as previously described [26]. 
BM-MNCs were separated by stratification on Lympholyte-H 1.077 g/cm3 gradient (Gibco-
(DMEM) supplemented with 1% penicillin/ streptomycin, L-glutamine, and 10% FBS), plated, and 
maintained in a humidified incubator at 37°C and 5% CO2. All nonadherent cells were removed 
after 24 hours. Medium was changed every 3 4 days until they reached 70 80% confluence. Cells 
were then trypsinized (Lonza, Verviers, Belgium), replated at a density of 3500 cells/cm2, and used 
for experiments within passages 3-4 after flow cytometry analysis for immunophenotype. 
 
BMSCs Coculture Assay 
In selected experiments, CBand mPB-derived CD34+ cells were cocultured either without stromal 
support or directly seeded on a confluent layer of BMSCs in 96-well plates for 24 hours before use. 
CD34+ cells were then harvested and used to perform clonogenic and migration assay as above 
described; in addition, the selected cytokines were added to the bottom chamber. After overnight 
incubation at 37°C in 5% humidified CO2 atmosphere, cells transmigrated into the lower chamber 
were recovered and counted, as previously described.  
 
Statistical Analysis 
Data are presented as mean ± SEM of at least three independent determinations. Statistical 
differences 
between groups were determined by a two-tailed Student t-test and one- or two-way ANOVA, as 
appropriate. All analyses were performed using GraphPad Prism software (version 6.0; La Jolla, 
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The role of circulating microvesicles (MVs) in Myelofibrosis (MF) and Essential Thrombocythemia 
(ET) is far to be defined.  Here we found that 1) circulating megakaryocyte-MVs were reduced in 
MF and ET while platelet-MVs were increased; 2) the proportion of circulating megakaryocyte- and 
platelet-MVs was associated with disease severity in MF; 3) ruxolitinib normalized the profile of 
circulating megakaryocyte- and platelet-MVs in spleen responders MF patients only. Of note, a cut-
off value of 19.95% of circulating megakaryocyte-MVs predicts ruxolitinib spleen response. In light 
of these findings, circulating megakaryocyte/platelet-MVs may have a tissue specific diagnostic and 





















Myelofibrosis (MF) and Essential Thrombocythemia (ET) are clonal disorders with 
abnormalities in megakaryocyte development and platelet activation, chronic inflammation and 
driver mutations (JAK2, CALR, MPL). 
negative (TN) patients. Ruxolitinib (JAK1/2 inhibitor) reduces splenomegaly and constitutional 
symptoms in MF. However, over 50% of patients fail to achieve or lose the response over time 
(Tefferi et al, 2015; Vainchenker et al, 2018).  
Extracellular microvesicles (MVs) are size-heterogeneous small vesicles (100-1000 nm) 
with pleiotropic effects on cell signalling including immunity and inflammation (Butler et al, 2018).  
Megakaryocyte- and platelet-MVs are the most abundant in peripheral blood (PB). However, while 
the MVs production by megakaryocytes is based on a constitutive mechanism, only activated 
platelets can produce CD62P+ MVs (Flaumenhaft et al, 2009). High serum levels of MVs have 
been detected in MF and ET (Caivano et al, 2015; Zhang et al, 2017).  
Circulating MVs as biomarkers of disease/malignancy in MPNs is an open question. Here 
we investigated: 1) the profile of MVs in MF and ET; 2) whether MVs proportions could be related 
to severity of MF; 3) the role of inflammation on MVs frequency of MF; 4) the effects of ruxolitinib 













Firstly, we characterized the circulating megakaryocyte- and platelet-MVs frequency. 
Comparing patients and healthy donors (HD; Fig 1a, 1b), megakaryocyte-MVs were significantly 
decreased in MF (p<0.001) and ET (p<0.001). By contrast, platelet-MVs were significantly 
increased in MF (p<0.01) and ET (p<0.001). Comparing patients groups, platelet-MVs were 
significantly increased in ET vs MF (p<0.01). No significant differences in megakaryocyte- and 
platelet-MVs distribution were observed between primary or post-PV/post-ET MF. According to 
mutation status (Fig 1c, 1d), the megakaryocyte-MVs of the JAK2(V617F)-(p<0.001)/CALR-(p<0.01) 
mutated and TN (p<0.01) MF patients were significantly decreased as compared to HD. 
Conversely, the platelet-MVs were significantly increased in the JAK2(V617F)-(p<0.001)/CALR-
(p<0.05) mutated MF patients only. Comparing the molecular subtypes, the platelet-MVs of the 
JAK2(V617F)-(p<0.05)/CALR-(p<0.05) mutated patients were significantly increased as compared 










































Fig 1. Circulating megakaryocyte- and platelet-MVs frequency of MF and ET patients. Megakaryocyte-
MVs (MK-MVs; CD61+CD62P-) and platelet-MVs (PLT-MVs; CD61+CD62P+) of MF (n=61), ET (n=20) 
patients and HD (n=20) are shown in panels (a) and (b). Panels (c) and (d) show the frequency of MK- and 
PLT-MVs of MF patients according to mutation status (JAK2(V617F) n=38; CALR n=11; MPL n=6 and TN 
n=6) and HD (n=20). In addition to individual data, median values and interquartile ranges are shown. 
(Kruskal-Wallis test; *p<0.05; **p<0.01; ***p<0.001) 
 
In ET patients (Supplementary Fig 2a, 2b), only the megakaryocyte-MVs of the 
JAK2(V617F)-(p<0.05)/CALR-(p<0.05) mutated patients were significantly decreased as compared to 
HD. By contrast, the platelet-MVs were significantly increased in JAK2(V617F)-(p<0.001)/CALR-
(p<0.01) mutated and TN patients (p<0.05). Comparing the three molecular subtypes, no significant 


















Supplementary Fig 2. Circulating megakaryocyte- and platelet-MVs frequency in ET according to 
mutation status. Megakaryocyte-MVs (MK-MVs; CD61+CD62P-) (a) and platelet-MVs (PLT-MVs; 
CD61+CD62P+) (b) frequency of ET patients (n=20) according to mutation status and HD (n=20) is 
shown. Results are reported as mean ± SEM.  (Kruskal-Wallis test; *p<0.05; **p<0.01; ***p<0.001) 
 
 
Secondly, we explored the circulating megakaryocyte- and platelet-MVs of the MF patients 
according to the IPSS risk score. Intermediate-2/high IPSS risk patients showed a significant 
decrease in megakaryocyte-MVs along with a significant increase of platelets-MVs as compared to 
intermediate 1/low IPSS risk patients (p<0.05 and p<0.01, respectively) and HD (p<0.001) (Fig 1e, 
1f). Comparing IPSS subgroups according to molecular subtypes and HD (Fig 1g, 1h), we observed 
that the megakaryocyte-MVs were significantly decreased in higher risk JAK2(V617F)-/CALR-
mutated patients (p<0.001, respectively). Concomitantly, the same group (higher risk JAK2(V617F)-
/CALR-mutated patients) presented a higher percentage of platelet-MVs (p<0.001, respectively), 




























Fig 1. Circulating megakaryocyte- and platelet-MVs frequency of MF patients. Panels (e) and (f) depict 
MK- and PLT-MVs frequency of MF patients according to IPSS risk (HR= intermediate 2/high IPSS risk 
(n=37); LR=intermediate 1/low IPSS risk (n=24)). Frequency of MK- and PLT-MVs of MF patients 
according to mutation status and IPSS risk is shown in panels (g) and (h) (JAK2(V617F)HR n=22; 
JAK2(V617F)LR n=16; CALR HR n=6; CALR LR n=5; MPL HR n=6 and TN HR n=3; TN LR n=3). In 
addition to individual data, median values and interquartile ranges are shown. (Kruskal-Wallis test; 
*p<0.05; **p<0.01; ***p<0.001) 
 
 
Surprisingly, we found a positive correlation between the megakaryocyte-MVs percentages 
of MF and platelets count (r=0.44; p<0.001; Fig 2a), suggesting a role of circulating 
megakaryocyte-MVs as biomarker of thrombopoiesis. In addition, the percentages of 
megakaryocyte-MVs of MF were inversely related to splenomegaly (r=-0.39; p<0.01; Fig 2b), 
confirming that a high disease severity is associated with reduced circulating megakaryocyte-MVs.
Of note, no correlation was found between platelet-MVs and platelets count or splenomegaly.   
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Fig 2. (a, b) Correlation between circulating megakaryocyte-MVs frequency and platelets count or 
splenomegaly in MF patients.  Megakaryocyte-MVs (MK-MVs; CD61+CD62P-) percentages (a) positively 
correlates with platelets count and (b) negatively with splenomegaly ( on test).  
 
 
Thirdly, despite crucial plasma pro-inflammatory cytokines and Thrombopoietin were 
increased in MF (Supplementary Table 4), only IL-6 plasma levels were inversely related with 
megakaryocyte-MVs percentages (r= -0.38; p<0.05; data not shown). We can therefore hypothesize 
that in MF IL-6 inhibits megakaryocyte-MVs production and/or increases their clearance. 
Conversely, the percentages of the platelet-MVs were positively correlated with the 
Thrombopoietin plasma levels (r=0.51; p<0.01; data not shown). Consistently, Thrombopoietin-
driven platelets activation has been previously described (Kojima et al, 1995). 
Finally, to investigate whether ruxolitinib therapy may affect circulating MVs, MF patients 
were studied before and after 6 months of therapy.  After 6 months, 12 out of 27 (44%) patients 
were in spleen response. At baseline, the percentages of megakaryocyte-MVs were significantly 
decreased as compared with the HD counterparts (spleen responders/non-responders p<0.001, 
respectively), while platelet-MVs significantly increased (spleen responders/non-responders 
p<0.001, respectively) (Fig 2c, 2d). Importantly, non-responders showed a significantly lower 
median percentage of megakaryocyte-MVs as compared with the spleen responders counterparts 
(p<0.05) (Fig 2c). To further explore whether megakaryocyte-MVs proportion could be linked to 
ruxolitinib response, we performed a ROC analysis. A cut-off value of 19.95% of megakaryocyte-
MVs was calculated with a specificity of 80%/sensitivity of 72% and discriminated the non-
responders (megakaryocyte-MVs < 19.95%). Ruxolitinib therapy, along with a significant decrease 
of platelet-MVs (p<0.01), promoted the release of megakaryocyte-MVs of spleen responders only 
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Fig. (c, d, e) Circulating megakaryocyte- and platelet-MVs frequency of MF patients according to 
ruxolitinib therapy response. (c) and (d) show megakaryocyte-MVs (MK-MVs; CD61+CD62P-) and 
platelet-MVs (PLT-MVs; CD61+CD62P+) of HD (n=20), spleen responders (SR; n=12) and non-responder 
(NR; n=15) MF patients before (T0) and after 6 months ruxolitinib therapy (6M). In addition to individual 
data, median values and interquartile ranges are shown. (Kruskal-Wallis test; *p<0.05; **p<0.01; 
***p<0.001). (e) the MK- and PLT-MVs combined profile of HD, spleen responders and non-responders 
before and after 6 months ruxolitinib therapy is shown (mean ± SEM).  
 
 
Interestingly, circulating monocyte- and endothelial-MVs (Supplementary Fig 3a, 3b) were 
significantly increased in MF patients (p<0.05 and p<0.01, respectively). At baseline, monocyte-
and endothelial-MVs were not significantly different between spleen responders and non-
responders. Ruxolitinib therapy decreased the endothelial-MVs frequency in spleen responders only 
(p<0.05). A trend, albeit not statistically significant, toward a reduction of the monocyte-MVs was 
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Supplementary Fig 3. Circulating monocyte- and endothelial-MVs frequency of MF patients according to 
ruxolitinib therapy response. Monocyte-MVs (MO-MVs; CD14+) and endothelial-MVs (E-MVs; 
CD144+/CD105+) frequency of HD (n=20), spleen responders (SR; n=12) and non-responder (NR; n=15) 
MF patients before (T0) and after 6 months ruxolitinib therapy (6M) are shown in (a) and (b), respectively. 










Overall, these results demonstrate that distinct abnormalities of circulating megakaryocyte-
and platelet-MVs profile are associated to MF and ET and suggest that: 1) platelets activation and 
abnormal/defective megakaryocytopoiesis may contribute to the increased/decreased proportion of 
circulating platelet- and megakaryocyte-MVs, respectively; 2) the activated JAK/STAT pathway 
plays a role in MVs biogenesis/clearance and, ultimately, in communication between 
megakaryocytes/platelets and the other cells.  Additionally, circulating megakaryocyte-MVs may be 
considered a biomarker of thrombopoiesis in MF.  Ruxolitinib therapy normalizes the profile of 
circulating MVs in spleen responders MF patients only by increasing the megakaryocyte-MVs and 
decreasing the platelet-MVs. Importantly, a cut-off value of 19.95% of megakaryocyte-MVs 
discriminates spleen responders and non-responders, demonstrating that circulating megakaryocyte-
MVs, as a liquid biopsy assay, may be used as potential tool to predict response to ruxolitinib 
therapy. Therefore, despite the need to be confirmed in a larger casistic, circulating 

















MATERIALS and METHODS 
Casistic 
This is a pilot study where patients were enrolled from May 2015 to May 2018. Sixty-one 
MF and 20 ET patients were included into the study. Patients were at diagnosis (n=31 MF; n=12 
ET) or at least 3 months after cytoreductive therapy (n=30 MF; n=8 ET) (Supplementary Table 1, 
2). Twenty-seven MF patients (24 JAK2(V617F)- and 3 CALR-mutated) at intermediate-1 (n=7), 
intermediate-2 (n=12) or high (n=8) International Prognostic Scoring System (IPSS) risk 
(O'Sullivan et al, 2018) were studied before and after 6 months of ruxolitinib therapy. Spleen 
response in ruxolitinib-treated patients was evaluated according to the 2013 International Working 
Group-MPN Research and Treatment criteria (Tefferi et al, 2013). Twenty age/sex-matched healthy 
donors (HD) were also included.  
 
Blood collection and Platelet Poor Plasma (PPP) preparation 
EDTA-anticoagulated PB was collected from patients and HD. The first 2 ml of blood were 
discarded. PPP was obtained (within 2 hours from blood collection) after two consecutive 
centrifugations at 2500 g for 15 minutes at room temperature. PPP was then aliquoted and stored at
-80°C until testing. The study was approved by the local Ethics Committee and was conducted 
accordingly to the Helsinki declaration (Informed consent was obtained from all subjects). 
 
Flow cytometry MVs identification 
Megakaryocyte-, platelet-, monocyte- and endothelial-MVs were analyzed in Platelet Poor Plasma 
(PPP; after thawing at 37°C) by flow cytometry (Cytoflex, Beckman Coulter, Milan Italy)
(Supplementary Fig 1 and Supplementary Table 3). The Violet Side Scatter laser (VSSC) is used 
as a trigger signal to discriminate the noise. To detect MVs the instrument was calibrated with 
MegaMix Beads (Stagò, Marseille, France). MVs identification was based on size (500-900 nm) 
and on the ability to bind lineage-specific monoclonal antibodies (Supplementary Fig 1 and
Supplementary Table 3). Matched isotype controls were used to select the cut-off. Results are 




Crucial plasma pro-inflammatory cytokines ( -
Necrosis Factor (TNF)- of MF patients and HD were analyzed by ELISA 
(R&D Systems, Milan, Italy).  
 
Genotype 
Molecular genotyping was performed as previously described (Romano et al, 2017).  
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6 using Kruskal-Wallis test, chi-square or 
Fisher exact test, as appropriate 




















Supplementary Fig 1. Gating strategy of circulating megakaryocyte- and platelet-MVs of 1 HD and 1 MF 
patient. (a) Fluorescence gated polystyrene beads of different sizes were used to determine the gates 
identifying big (500-900 nm), small (200-300 nm) and nano (100-160 nm) MVs. Gating strategy to identify 
big MVs (500-900 nm) is shown. (b) and (c) show representative dot-plots of megakaryocyte- and platelet-
MVs in plasma samples from 1 HD and 1 MF patient. Using the defined gate for big MVs, all events positive 













































Supplementary Table 1. Clinical and laboratory features of MF patients according to mutational status 
PMF: Primary Myelofibrosis; PPV-MF: Post Polycythemia Vera-Myelofibrosis; PET-MF: Post Essential 
Thrombocythemia-Myelofibrosis. The presence of 0, 1, 2 or 3 and >4 adverse factors defines low, 
intermediate-1, intermediate-2 and high-risk disease. IPSS, International Prognostic Scoring System. 
Comparisons of variables between groups of patients were carried out by Kruskal-Wallis test and by chi-
square or Fisher exact test, as appropriate. No significant differences were observed among groups, except 













Median age, years (range) 70 (40-84) 65,5 (40-82) 72,5 (61-84) 65,5 (56-76) 77 (60-84) 
 
Males, no. (%) 30 (49%) 19 (50%) 7 (64%) 1 (17%) 3 (50%) 
Median Hemoglobin, g/dl; 
median (range) 
 
11,5 (7,1-15,1) 12,4 (7,1-15,1) 10,0 (7,7-4,9) 9,1 (7,2-10,8) 9,7 (8,1-14,3) 
Median Leukocytes, 
x 109/l; median (range) 
 
9,4 (2,2-80,1) 9,4 (2,2-80,1) 7,5 (4,3-20,1) 15,9 (6,2-39,5) 10,8 (2,5-7) 
Median Platelets, 
x 109/l; median (range) 
 
229 (38-845) 229 (65-631) 217 (90-845) 280 (46-632) 121 (38-613) 
Median Lymphocyte 
x 109/l; median (range) 
 
1,7 (0,4-16,3) 1,4 (0,4-15,8) 1,85 (1,1-6) 2,4 (0,8 -16,3) 4,1 (0,4 -11,7) 
Median Monocyte 
x 109/l; median (range) 
 
0,6 (0,1-5,9) 0,6 (0,1-5,5) 0,6 (0,3-4,4) 1,3 (0,4-5,9) 0,7 (0,2-5,3) 
BM fibrosis, no. of 
patients (%) 
     
Grade 1 30 (49%) 19 (50%) 5 (46%) 3 (50%) 3 (50%) 
Grade 2 23 (38%) 14 (37%) 4 (36%) 2 (33%) 3 (50%) 
Grade 3 8 (13%) 5 (13%) 2(18%) 1 (17%) 0 
IPSS, 
Number of patients 
     
Low 4 (7%) 4 (10%) 0 0 0 
Intermediate-1 20 (33%) 12 (32%) 5 (45,5%) 0 3 (50 %) 
Intermediate-2 16 (26%) 11 (29%) 1 (9%) 3 (50%) 1 (17 %) 
High 21 (34%) 11 (29%) 5 (45,5%) 3 (50%) 2 (33 %) 
Previous treatment, 
no of patients (%) 
     
Hydroxyurea 30 (49%) 19 (50%) 3 (27%) 4 (67%) 4 (67%) 
WHO Diagnosis      
PMF 39 (64%) 22 (58%) 7 (64%) 5 (83%) 5 (83%) 
PPV-MF 14 (23%) 14 (37%) 0 0 0 















Supplementary Table 2. Clinical and laboratory features of ET pts according to mutational status No 
significant differences were observed among groups. Comparisons of variables between groups of patients 




MVs type Identified as List of monoclonal antibodies 
Megakaryocyte-MVs CD61+/CD62P- Anti-CD61 (Clone: SZ21; FITC-conjugated; Catalog number 
IM1758);  
Anti- CD62P (Clone: CLB-THROMB/6; PE-coniugated; Catalog 
number IM1759U). 
All antibodies from Beckman Coulter S.r.l. 
Platelet-MVs CD61+/CD62P+ Anti-CD61 (Clone: SZ21; FITC-conjugated; Catalog number 
IM1758);  
Anti- CD62P (Clone: CLB-THROMB/6; PE-coniugated; Catalog 
number IM1759U). 
All antibodies from Beckman Coulter S.r.l. 
Monocyte-MVs CD14+ Anti-CD14 (Clone: RM052; FITC-conjugated; Catalog number 
B36297) from Beckman Coulter S.r.l.; 
Endothelial-MVs CD144+/CD105+ Anti-CD144 (Clone: REA199; FITC-conjugated; Catalog number 
130-100-742) from Miltenyi Biotec; 
Anti- CD105 (Clone; TEA3/17.1.1; PE-coniugated; Catalog 
number B92442) from Beckman Coulter S.r.l. 
 











Median age, years (range) 65,5 (61-79) 66 (61-72) 65 (63-79) 69 (62-76) 
Males, no. (%) 8(40%) 4 (30,8%) 3 (60%) 1 (50%) 
Median Hemoglobin, g/dl; 
median (range) 
 
13,7 (10-16,2) 13,7 (10-15,2) 13,5 (10,9-16,2) 12,6 (10,5-14,8) 
Median Leukocytes, 
x 109/l; median (range) 
 
7 (4,7-15,45) 8,7 (7-15,45) 6,5 (5,7-7,3) 5,3 (4,7-5,8) 
Median Platelets, 
x 109/l; median (range) 
 
647 (542-1069) 655 (542-1069) 639 (631-939) 665 (617-712) 
Previous treatment, 
no of patients (%) 
    












Supplementary Table 4. Plasma levels of crucial pro-inflammatory cytokines and thrombopoietin were 
increased in MF patients - -
Thrombopoietin (TPO) plasma levels of HD (n=20), total MF patients (n=61) measured by ELISA. Results 



































Total MF  
(cases 61) 
P-value 
IL-  0,2 (0-4,5) 1,5 (0,07-8,5) <0.01 
IL-6 5,4 (4,5-32,8) 24,8 (1,2-259) <0.001 
IFN-  0,2 (0,02-0,8) 1,3 (0-6,4) <0.0001 
TNF-  0,4 (0-13,3) 6,8 (0,05-39,2) <0.0001 
TPO 22,2 (11,2-88) 124,4 (10,4-539,7) <0.01 
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Myelofibrosis (MF) is characterized by clonal hemopoiesis, inflammatory microenvironment and 
mutations in JAK2, MPL, or CALR genes. Around 10% of patients (pts) do not carry the 3 
mutations (Triple negative, TN) and show reduced survival (1).  Microvesicles (MVs; 0.1 - 1 µm) 
are small vesicles deriving from the cell plasma membrane with a role in intercellular signalling (2). 
MVs can express antigens, and contain components (protein, mRNA, microRNA (miRs) from their 
cell of origin that determines their composition, characterization, and transfer of biologic 
information. Peripheral blood contains MVs deriving from megakaryocytes, platelets, leukocytes, 
red blood and endothelial cells. megakaryocytes- and platelets-MVs are the most abundant.
Circulating MVs are increased in inflammation and cancer including MF. miRs contribute to MF 
pathogenesis (3). However, in MF the miRs profile of circulating MVs has never been investigated. 




Card-based analysis demonstrated that many miRs were significantly upregulated in MVs from both 
JAK2(V617F) mutated and TN pts as compared with the HD counterparts (Figure 1A, B). Among 
them miR-21, known to be the most commonly upregulated miR in haematological tumours, is an 
anti-apoptotic factor with oncogenic potential and able to inhibit megakaryocyto-erithropoiesis
(4,5). MiR-155, 222, 24 were upregulated in TN-MVs only. MiR-155 is upregulated in response to 
inflammation and, targeting p53 pathway, inhibits apoptosis. Its overexpression stimulates granulo-
monocytopoiesis while impairing megakaryocytopoiesis (5). MiR-221/222, markers of poor 
prognosis in aggressive tumours and both increased in TN-MVs, show anti-apoptotic effect acting 
downstream of the oncogenic RAS-RAF-MEK pathway (5, 6). MiR-423-5p and miR-34a-5p, both 
pro-apoptic miRs (5, 8), show high expression in JAK2(V617F) and TN-MV, but are almost absent in 
HD counterparts. MiR-34a-5p is shown to be associated with MF (8), however, its expression is 
lower in TN-MV. Interestingly, many miRs regulating inflammation (miR-21, 146a, 223, 19a) and 
proliferation (miR-212-3p, -127-3p, -199a-3p, 21, 99b) were overexpressed in pts-MVs (5). Finally, 
miR-155, 146a, 19a and 194 overexpression affects the JAK-STAT pathway by blocking SOCS3, a 
negative regulator of the JAK-STAT signalling, and promoting cell survival. Comparing TN vs 
JAK2(V617F) MVs (Figure 1C), the expression of 6 miRs (miR-122, 27a, 744, 584c, 365, 483-5p) 
was increased, whereas 2 onco-suppressors miRs (let-7b and miR-361-5p) were less expressed. Of 
note, 6 out of the above mentioned 8 miRs have SRSF1 gene as a common target which is both a 
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Figure 1. miRs profiling-Card analysis: comparisons with fold change of significantly different miRs
between A) JAK2 pts and HD; B) TN pts and HD; C) JAK2 and TN pts. 
 
Based on card analysis, we selected 21 miRs (-122-5p, -27a-3p, -365a-3p, -361-5p, let7b-5p, -744-
5p, -548c-3p, -15b-5p, -221-3p, -202-3p, -212-3p, -409-3p, -24; -146a, 19a, -21, -155, -34a-5p, -
127-3p, -222, -423-5p) to be validated with RT-PCR as potential circulating MV-associated 
signature. MiRs were selected 30) and amplification score 
(AmpScore >/= 1.24).  (V617F)
and TN-MVs were included in the study.  
First, we investigated the difference between HD and total MF pts, and 4 miRs (-212-3p, -127-3p, -
222, -34a-5p were significantly increased in MF-MV p<0.05 and p<0.001, respectively), as 
reported in Figure 2.  
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Figure 2. miRs profiling validation-RT-PCR analysis:  comparison between MV from total MF patients and 
HD.  The expression of miR-212-3p, -127-3p, -222 and -34a-5p were significantly increased in MF MVs. 




Secondly, to identify whether miRs expression differs between JAK2(V617F)/TN-MV and HD-MV,
we analysed the miR cargo of MVs according to the mutational status. As reported in Figure 3, 
miRs -127-3p and -34a-5p resulted significantly upregulated in JAK2(V617F)-MV as compared to HD
(p<0.05 and p<0.01, respectively), while only miR-34a was overexpressed in TN-MV (p<0.05). 
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Figure 3. miR profiling validations-RT-PCR analysis comparison between TN/JAK2(V617F) and HD MV. 
miR-127-3p and miR-34a-5p were significantly increased in MVs from patients. Data are reported as mean 










Finally, we compared the miR expression of JAK2(V617F) and TN-MV and only miR-361-5p was 
significantly increased in TN-MV as compared with the JAK2(V617F) counterparts (p<0.05; Figure 
4). 
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Figure 4. miRs profiling validation-RT-PCR analysis comparison between TN and JAK2(V617F) MVs. MiR-
361-5p expression was significantly increased in TN-MV as compared with the JAK2(V617F) counterparts. 













These results demonstrate that the miR profile of circulating MVs from MF patients is different 
from the normal counterparts and varies according to mutational status. Specifically, we found an 
upregulation of selected miRs, namely miR, -127-3p, -34a-5p -222, and -212-3p, in MF-MVs as 
compared to the normal counterpart. Analyzing patients according to the mutational status, only the 
MVs of JAK2(V617F) mutated patients show a significant upregulation of miR-127-3p compared to 
HD-MVs, while the miR-34a was overexpressed in both JAK2(V617F)-/TN-MVs.  
A previous study analysed differentially expressed genes and miRs in CD34+ cells from peripheral 
blood of patients with MF and found miR-127-3p to be upregulated. In particular, miR-127-3p was 
negatively associated with biological processes related to cell cycle and mitosis, suggesting that the 
high expression of miR-127-3p inhibits the proliferation of stem cells in peripheral blood (7). 
Therefore, miR-127-3p can function as a tumor suppressor and its high expression, also 
demonstrated in JAK2(V617F) -MVs, may influences the CD34+ cell cycle in peripheral blood, thus 
affecting the disease behaviour. 
MiR-34a-5p is defined as tumor suppressor miR and its upregulation was found in the CD34+ 
hemopietic stem/progenitor cells (HPCs) of MF (8). Furthermore, they found that enforced 
expression of miR-34a-5p partially constrains proliferation and favours the megakaryocyte and 
monocyte/macrophage commitment of HPCs. The upregulation of miR-34a-5p in MF CD34+ cells 
and MF-MVs could be involved in the hyperplastic megakaryopoiesis and in some alterations of the 
bone marrow that are a hallmark of MF pathogenesis. 
MiR-222 is associated with hematopoietic transformation of myeloid, erythroid and megakaryocytic 
progenitor cells during hematopoiesis (9). Mir-222 normally suppresses erythropoiesis by targeting 
c-KIT and is downregulated during the in vitro erythroid differentiation of CD34+ peripheral blood 
cells from healthy donors (10). Tombak A. et al., analyzing the miRs profile in the peripheral blood 
of patients with myeloproliferative neoplasms (MPN), reported that miR-222 expression was lower 
in Polycythemia vera (PV) patients and higher in Essential Thrombocythemia (ET) and MF patients 
as compared to control group (9). As suggested by Tombak A. et al, the detection of higher
expressions of miR-222 in the peripheral blood from MF patients probably derives from an 
excessive cell proliferation. Interestingly, it has been hypothesized that, elevated mir-222 levels 
may contribute to anemia in MF by suppressing erythropoiesis. Therefore, this miR can be used as 
therapeutic targets for the treatment of anemia in MF (9). 
Excluding the miR -127-3p, -34a-5p and -222, which have been previously described to be 
associated to MF, the other miRs (-212-3p and -361-5p), we found to be upregulated in MF-MVs,
have never been described in MF. 
MiR-212-3p promotes cell cycle progression, cell proliferation, migration, and invasion of non-
small cell lung cancer and these effects are partially reversed by the miR-212-3p inhibitor or anti-
miR-212-3p (11). These results suggest that miR-212 might have tumor-promoting properties. 
Potential targets of miR-212 is the tumor suppressor PTCH1, which may be responsible for the 
effect of miR-212-3p on cell proliferation (11). Furthermore, miR-212-3p was found to be 
downregulated in human Adult T-cell leukemia/lymphoma (ATL) cell lines as compared to normal 
T lymphocytes (12). Conversely, miR-212-3p restoration significantly inhibited ATL cell 
proliferation by repressing CCND3 expression (12). Therefore, the effect of miR-212 could be cell-
or tumor- dependent and it would be interesting to study the effect of mir-212-3p in the context of 
MF and in particular, the effect of circulating MF-MVs, which show an upregulation of miR-212-
3p, on different cell types. The upregulation of miR-212-3p in MF-MVs could be involved in 
hyperplastic hematopoiesis and in specific alterations of the immune system of MF. 
Importantly, 4 miRs (-212-3p, -222, -127-3p and -34a-5p) overexpressed in MF-MVs have 
PABPC1 gene as a common target. This gene is involved in the processing and translation of 
mRNAs. The present study is still ongoing and validation of selected miR targets expression 
including PABPC1 is under investigation. 
Interestingly, MiR-361-5p is significantly upregulated in TN-MVs as compared to JAK2-MVs. It
was reported to suppress proliferation, migration and invasion of cancer cells in different tumors
(13, 14, 15, 17). MiR-361-5p is downregulated in numerous human cancers, including cutaneous 
squamous cell carcinoma (14), gastric cancer (15), colorectal cancer (15) and prostate cancer (17). 
In these cancers, MiR-361-5p functions as a tumor-suppressor miRNA through directly binding to 
staphylococcal nuclease domain containing-1 (SND1), an endonuclease that regulates miRs 
involved in G1-to-S phase transition (13, 15, 16 For example, in colorectal cancer, miR-361-5p
expression was negatively correlated with pulmonary metastasis and disease progression. 
Furthermore, the ectopic expression of miR-361-5p suppressed cell proliferation, migration and 
invasion by targeting SND1 (15). Liu et al showed that miR-361 inhibits prostate cancer growth and 
improves apoptosis (17). However, in cervical cancer, miR-361 has been reported to be 
upregulated, acting as an oncogene (18). The forced expression of miR-361 significantly increased 
the growth, migration and invasion of cervical cancer cells acting as a mediator of epithelial-
mesenchymal transition (18). These conflicting results indicates that the expression and functions of 
miR-361-5p in tumors are tissue-specific. 
Identification of miR-361-5p targets and functions would be important, especially to understand its 
role in circulating MVs and disease of TN patients.  
Finally, the effects of miRs may be cell- or tumor- dependent, so it would be interesting to perform 
functional tests to investigate the effect of MF-MVs and of their upregulated miRs cargo, on 




In conclusion, here we performed for the first time a characterization of miRs profile in circulating 
MF-MVs. Here we identified a miR signature of MF-MVs. Specifically, circulating TN-MVs show
distinct miR signature as compared with the JAK2(V617F) mutated counterparts. This study has the 
potential to identify disease-related biomarker(s) and may provide a useful molecular target for MF 
diagnosis and treatment. We aim to increase our casistic in order to confirm these findings in MF-
















MATERIALS and METHODS 
 
Casistic 
Peripheral blood was collected from MF pts (at diagnosis or out of cytotoxic treatment for at least 3 
months) and age/sex-matched healthy donors (HD-n=10)). MF pts were JAK2(V617F) mutated (n=10) 
and TN (n=6).  
 
MVs isolation and count 
After platelet poor plasma (PPP) collection, MVs were isolated from PPP by ultracentrifugation
(45.000 rpm for 2 hours at 4°C) and quantified using the Nanosight technology.  
 
MicroRNA expression assay 
MiR expression of isolated MVs (109) was investigated after RNA extraction with the miRNeasy 
Mini Kit and , 3 
JAK2(V617F)  and 3 TN pts. RT-qPCR validation assay was performed on 10 HD, 10 JAK2(V617F)
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Myelofibrosis (MF), a clonal neoplasia of the hemopoietic stem/progenitor cell, is associated 
with mutations in Janus Kinase 2 (JAK2) and calreticulin (CALR) genes. Chronic inflammation is 
the hallmark of MF. Infectious complications are the leading cause of morbidity and mortality. 
Based on this scenario, here we functionally evaluated key immune-cell subsets with the aim to 
investigate their putative role in immunosurveillance.  
We found that MF patients (33 untreated patients - 20 JAK2(V617F) and 13 CALR mutated) 
were characterized by a reduced capacity of monocytes to differentiate into dendritic cells (DCs), 
reduced T-helper (Th) 17 plasticity and hypo-functional innate lymphoid cells (ILC). Furthermore, 
these patients showed reduced plasma levels of interleukin (IL)-4, -5 and Interferon- -
concomitant increase of IL- -6, -17, and Tumor Necrosis Factor- -
analysed the results according to the mutational status showing that patients carrying JAK2(V617F)
mutation presented a reduction in Th17, myeloid-DCs and effector Tregs as well as an increase in 
ILC1. CALR-mutated patients revealed increased ILC3 levels, reduced Th1 and their monocytes had 
reduced capacity to mature in vitro into fully committed DCs. Their Tregs were also less effective 
in inhibiting the proliferation of autologous effector T-cells because of an increased proliferative 
status induced by CALR mutation.  
Here, we have demonstrated that MF patients carry mutations that lead to phenotypic and 
functional alterations in key immune cell subsets. These alterations, contributing to the 
generation/maintenance of the inflammatory microenvironment, may have a potential role in 
susceptibility to infections and disease progression. 
Background 
Myelofibrosis (MF) refers to the Philadelphia chromosome-negative myeloproliferative 
neoplasms (MPNs) originating in the multipotent hematopoietic stem cells. It is clinically 
characterized by progressive anemia, splenomegaly, debilitating constitutional symptoms and by an 
increased risk to evolve in acute leukemia [1]. MF can develop de novo as primary MF (PMF) or 
secondary either from Polycythemia Vera (PPV-MF) or Essential Thrombocythaemia (PET-MF).
Approximately 60% of MF patients carry a mutation in the Janus Kinase 2 (JAK2) [2] gene, and an 
additional 10% in the myeloproliferative leukemia protein gene (MPL). Mutations in Calreticulin 
gene (CALR) have been reported in about 80% of JAK2 and MPL unmutated patients [3]. Of note,
regardless the driver mutations, the JAK-STAT signalling pathway is hyper-activated in all the
MPNs [4].  
Chronic inflammation, as result of aberrant cytokines production by mutated and unmutated 
cells, is considered the MF hallmark. In this scenario, infectious complications are the leading cause 
of morbidity and mortality constituting more than 10% of all patient deaths [5,6]. In order to
understand whether the atypical infectious events are caused by deficits in the innate or adaptive 
immune response, a comprehensive analysis of key immune cells is required.  
To date, it is well established that in PMF, the monocytes composition is different with a 
reduction in the classical (CD14brightCD16-) compartment [7]. Monocytes can differentiate, under 
inflammatory conditions, in dendritic cells (DCs); however, no data have been published so far 
about the ability of MF monocytes to differentiate into DCs. DCs are a heterogeneous group of 
professional antigen-presenting cells (APCs) including plasmacytoid (pDC), and myeloid (mDCs) 
DCs [8]  . Thus far, no data have been reported on the frequency of circulating DC subsets in MF.  
A recent report studied the T helper (Th)1, Th2 and Th17 compartments in MPNs patients 
under treatment. Of note, no differences between healthy donors and patients were found in Th cells 
polarization at baseline level [9]. Thymus derived regulatory T cells (Tregs) frequency has been 
already studied in MPNs, however conflicting results have been published [10 12]. 
MPNs, have reduced natural killer cell (NKs) compartment with impaired function [13,14].
NKs are part of the recently described family of innate lymphoid cells (ILCs), which play a role in 
autoimmunity, inflammation [15] and tumour immunosurveillance [16]. Beside conventional NKs, 
three distinct ILCs subsets have been described based on their transcriptional regulation and 
cytokine profiles mirroring those of Th cells [17]. We and others recently showed that acute
myeloid leukaemia patients present an impaired ILC compartment [18,19] but no data are available
in MF.  
Based on this background and considering the essential role of the JAK/STAT pathways in
shaping the immune response [20], we functionally evaluated key immune-cell subsets with the aim 
to investigate their putative role in immunosurveillance. We found that MF patients are 
characterized by a state of mutation-dependent immune alterations with key cellular components of 








33 MF patients were included in the study. Baseline features of the entire cohort are detailed 
9/L) was observed in 4 patients, while 6 patients had a 
9 9/L) and monocytosis (monocytes 
9/L) were present in 14 and 9 patients, respectively. We studied 18 patients at the diagnosis 
while 15 patients received previous treatment for MF (Hydroxyurea/Ruxolitinib), as detailed in 
Table 1. In all cases, therapies had been discontinued for at least two months before sample 

























Table 1. Clinical and laboratory features of MF patients according to mutational status 
  Total MF  
(33 cases) 
JAK2(V617F)+  




Median age, years (range) 70 (40-84) 67,5 (40-82) 73 (67-84) 0.02 
Males, no. (%) 16 (48.4%) 9 (45%) 7 (54%) 0.72 
Median Hemoglobin, 
g/dl; median (range) 
11 (7.7-15.1) 12.6 (9.2-15.1) 9.3 (7.7-14) 0.001 
Median Leukocytes, 
x 109/l; median (range) 
7.3 (2.3-48.3) 9.3 (2.5-26.4) 6.4 (2.3-48.3) 0.6 
Median Platelets, 
x 109/l; median (range) 
216 (41-549) 248 (41-549) 175 (90-419) 0.26 
Median Lymphocyte 
x 109/l; median (range) 
1.5 (0.5-10.7) 1.45 (0.5-2.7) 1.6 (0.5-10.7) 0.16 
Median Monocyte 
x 109/l; median (range) 
0.6 (0.1-7.6) 0.58 (0.19-1.8) 0.6 (0.1-7.6) 0.23 
BM fibrosis, no. of patients (%)     
Grade 1 11(33%) 11(55%) 0 (0%) 0.0016 
Grade 2 15 (46%) 6 (30%) 9 (69%) 0.03 
Grade 3 7 (21%) 3(15%) 4 (31%) 0.39 
IPSS, 
Number of patients 
    
Low 3 (9%) 3 (15%) 0 (0%) 0.53 
Intermediate-1 16 (49%) 11 (55%) 5 (38%) 0.48 
Intermediate-2 4 (12%) 3 (15%) 1 (8%) 1 
High 10 (30%) 3 (15%) 7 (54%) 0.025 
Unfavorable Karyotype, 
no of patients (%) 
3 (9%) 3 (15%) 0 (0%) 0.26 
Previous treatment, 
no of patients (%) 
    
Hydroxyurea 11 (33%) 9 (45%) 2 (20%) 0.24 
Ruxolitinib 4 (12%) 2 (10%) 2 (15%) 1 
WHO Diagnosis     
PMF 22 (67%) 14 (70%) 8 (62%) 0.71 
PPV-MF 4 (12%) 4 (20%) 0 (0%) 0.14 
PET-MF 7 (21%) 2 (10%) 5 (38%) 0.08 
 
PMF: Primary Myelofibrosis; PPV-MF: Post Polycythemia Vera-Myelofibrosis; PET-MF: Post Essential 
Thrombocythemia-Myelofibrosis. The presence of 0, 1, 2 or 3 and >4 adverse factors defines low, intermediate-1, 
intermediate-2 and high-risk disease. IPSS, International Prognostic Scoring System; unfavorable karyotype (presence 
of one or two abnormalities including þ8, 7/7q-, i(17q), inv(3), 5/5q-, 12p- or 11q23 rearrangement). P value between 




Dysregulated plasma levels of cytokines involved in differentiation/function of 
immune cells in MF patients  
We firstly evaluated the plasma levels of cytokines involved in the differentiation and 
function of different immune cell types. In agreement with previous reports [23,24], we found 
reduced plasma levels of IL-4, -5 and IFN- - -6, -10, -
17, and TNF- see Additional tables). Of note, IL-12 and -13 plasma 
levels from CALR mutated patients were not significantly different from the normal counterparts. 
No correlation between allele burden and cytokine plasma levels was observed, with the notable 
exception of TNF- JAK2(V617F) allele burden.  
Irrespective of mutational status, IL-12 and -13 plasma levels were negatively correlated with the 
IPSS score values (R=0.47; p<0.04; R=0.49; p<0.04, respectively). Conversely, we found a positive 
correlation between circulating IL-6 levels and splenomegaly/fibrosis (R=0.46; p=0.018 and 





Reduced circulating mDCs in JAK2(V617F) mutated patients 
Afterwards, we evaluated the number of circulating mDCs and pDCs in MF patients and 
controls (Figure 1A). As shown in Figure 1B, circulating mDCs were significantly reduced in MF 
status, this reduction was significant only in JAK2(V617F) 
not in CALR mutated patients. No significant differences were observed in the number of 















Figure 1. Reduced circulating mDCs in JAK2(V617F) mutated patients. A) Representative example of the 
gating strategy used to determine, in HD (left panels) and MF patients (right panels), the percentages used 
to calculate the circulating level of mDCs (identified as Lin- HLA-DR+CD11c+ cells) and pDCs (identified 
as Lin-HLADR+ CD123+ cells). Circulating number of mDCs (B) and pDCs (C) in HD (n= 17), total MF (n 
D 27), JAK2(V617F) mutated (n=13), CALR mutated (n= 9) and triple negative (n=5) patients are shown; 
cell concentrations were calculated as follows: (percentage of positive cells) x (white blood cell count)/100. 






Impaired DC differentiation capacity of monocytes from MF patients 
 
Monocytes can differentiate into DCs in vivo mainly in infected or inflamed tissues, leading 
to the concept that monocytes are a precursor of inflammatory DCs. We thus studied the capacity of 
freshly isolated monocytes to differentiate into DCs in vitro. After 5 days culture, the phenotype of 
immature mo-DCs was evaluated by flow cytometry (Figure 2A). As shown in Figure 2A, 
monocytes from CALR but not those from JAK2(V617F) mutated patients were not able to 
differentiate into immature DCs, as indicated by the persistence of CD14 expression. In addition, 
irrespective of mutational status, immature mo-DCs failed to up-regulate CD1a (85±4.6% vs 
69.7±19.6%
the normal counterparts. We then assessed the capacity of immature mo-DCs to mature in the 
presence of the previously described inflammatory cocktail. Surprisingly, immature mo-DCs were 
able to respond and mature as the healthy counterpart (Figure 2B). However, mature mo-DCs from 
CALR 
ared to the normal counterparts.  
To investigate whether the impaired DCs phenotype was associated with altered function, 
we firstly assessed the ability of immature mo-DCs to prime allogeneic T-cell responses in vitro. 
Regardless of mutational status, pat -DCs were unable to stimulate T cell 
proliferation to the same extent as the HD counterpart (Figure 2C). This data is supported by the 
defective CD25 up-regulation in T cells (Figure 2D). Migration towards the lymph node and the 
capacity to capture antigens are essential for DCs function. For this reason, we performed migration 
and endocytosis assays. No significant differences were found in the migratory capacity of MF-
derived mature mo-DCs, both spontaneous or in the presence of CCL19, a chemokine essential for 
lymph node homing (Figure 2E). However, MF-derived immature mo-DCs were more efficient in 
capturing the antigen than the control counterparts (Figure 2F).  
These results show an impaired MF-monocyte capacity to differentiate in vitro into mo-DCs 













Figure 2. Impaired DCs differentiation capacity of monocytes from MF patients. Immature (A) and mature (B) mo-
DCs phenotype from HD (n=10) total MF (n=16), JAK2(V617F) mutated (n=7), CALR mutated (n=5) and triple 
negative (n=4) patients. The expression of HLA-DR, CD14, CD1a, CD40, CD80 and CD86 was evaluated by flow 
cytometry. Histograms represent the mean percentage of expression ± SD; C) ability of mo-DCs from HD (n= 8), total 
MF (n=8) to prime allogeneic T-cell responses in vitro. mo-DCs were cultured with allogeneic Tresp (mo-DCs/Tresp 
ratio 1:10) labeled with CFSE. The assays were performed over a period of 5 days and T cell proliferation was 
evaluated by division index. Histograms represent the mean § SD of the division index expressed as percentages; D) 
mo-DCs were cultured with allogeneic Tresp (mo-DCs/Tresp ratio 1:10) labeled with CFSE. The assays were 
performed over a period of 5 days and CD25 expression was evaluated by flow cytometry. Histograms represent the 
mean MFI ± SD of CD25 from HD (n=8) and total MF (n= 8) to prime allogeneic T-cell responses in vitro; E) 
evaluation of spontaneous and toward CCL19 (400 ng/mL) mature mo-DCs migratory capacity in HD (n= 6) and MF 
patients (n= 8). 1×105 cells were seeded in a transwell chamber (diameter 6.5 mm, pore size 8 mm) for 4 hours. The 
amount of migrated cells is expressed as a percentage of the input: (number of migrated cells in the lower 
compartment/loaded cells in the upper compartment) X 100. Histograms represent the mean ±SD of the input; F) 
Immature mo-DCs dextran uptake in HD (n=6) and MF patients (n=8). Cells were incubated for 30 min at 37°C or on 
ice (used as a background control). After washing, fluorescence was analyzed by flow cytometry. Uptake of FITC-
dextran was expressed as delta (D) mean fluorescence intensity (MFI): MFI (uptake at 37°C)  MFI (uptake on ice). 







Reduced Th1 compartment in CALR mutated patients 
Th cells play critical roles in the development and progression of infections, autoimmune 
diseases and tumours. Here, we firstly analysed the circulating quota of CD3+CD4+ cells and no 
significant differences between MF and HD were found (data not shown). These data were 
confirmed even when the percentages of total CD3, CD4 and CD8 positive cells have been 
evaluated in PBMCs (Figure 3A). However, when we evaluated the Th1 and Th2 balances [25], we 
(Figure 3B and C). Interestingly, only CALR mutated patients showed a significant reduction of Th1 





Figure 3. Reduced Th-1 compartment in CALR mutated patients A) Percentages of CD3+, CD3+CD4+, 
CD3+CD8+, CD3+CD4+ CD45RO+ cells on PBMC from HD (n=14),total MF (n =16), JAK2(V617F) 
mutated (n=7), CALR mutated (n=5) and triple negative (n D 4) patients evaluated by flow cytometry; B) 
Representative example of the gating strategy used to determine by flow cytometry, in HD (left panels) and 
MF patients (right panels), the percentages used to identify Th-1 and Th-2 (identified as 
CD3+CD4+CD45RO+CXCR3+CRTH2-CCR6- and CD3+CD4+CD45RO+CXCR3-CRTH2+ 
cells,respectively); C) Percentages of Th1 and Th2 cells on the CD3+CD4+CD45RO+ population from HD 
(n=14), total MF (n=16), JAK2(V617F) mutated (n=7) and CALR mutated (n=5) and triple negative (n=4) 
patients. Histograms represent the mean percentages ± SD  
Reduced Th17 compartment in JAK2(V617F) mutated patients  
Th17 can promote anticancer immunity; however, these cells exhibit also tumor-promoting 
properties. This dichotomy in cancer may be related to the versatile nature of these cells [26].  
In MF the mean number of circulating Th17 was reduced as compared to HD (25.22±17.8 vs 
mutational status, only JAK2(V617F) mutated patients showed a statistically significant reduction 
intermediate Th populations recently described based on the expression of chemokine receptor and 
their capacity to secrete IL-17/IFN-
[27,28]. We found that MF patients showed a reduced percentage of circulating Th17/Th1 
 











Figure 4. JAK2(V617F) mutated patients show a reduced Th17 compartment. A) Representative example 
of the gating strategy used to determine by flow cytometry, in HD (left panels) and MF patients (right 
panels), the percentages used to calculate the circulating level of Th17 (identified as 
CD3+CD4+CCR6+CD161+ cells); B) PB circulating number of Th17 in HD (n=19), total MF (n =23), 
JAK2(V617F) mutated (n=10) CALR mutated (n=8) and triple negative (n=5) patients; cell concentrations 
were calculated as follows: (percentage of positive cells) x (Lymphocyte count)/100. Each symbol represents 
one individual and the height of the bar represents the mean; C) Percentages of Th17/Th1 and Th17/Th22 
(identified as CD3+CD4+CD45RO+CXCR3+CRTH2-CCR6+ and CD3+CD4+CD45RO+CXCR3-CRTH2-
CCR6+ cells, respectively) in HD (n=14), total MF (n=16), JAK2(V617F) mutated (n=7) CALR mutated 







JAK2(V617F) mutated patients present an abnormal natural Treg heterogeneity in 
periphery 
When we analysed the number of circulating Tregs we did not find any significant 
difference between patients and controls (Figure 5A). However, considering the three Treg sub-
populations recently described by Miyara et al.  [29] we found a reduction of the effector Tregs 
compartment identified as CD3+CD4+CD45RA-CD25brightCD127low 
5B and C). Nevertheless, the analysis according to the mutational status revealed that JAK2(V617F)
but not CALR mutated patients, showed this reduction (Figure 5C). In addition, we also found an 
inverse correlation between IL-12 plasma levels and the percentages of Population II Tregs 
(R=0.68; p<0.02). 
To further understand the Treg role in MF we tested their suppressive ability in vitro and no 
significant differences were observed between patients and controls (data not shown). However, we 
found that Tregs from CALR, but not those from JAK2(V617F) mutated patients, do not show 
inhibition of T cell proliferation as effectively as the normal counterparts (Figure 5D). In that 
regard, the effect of CALR mutation in T cell activation has been described [30]. Specifically, Tregs 
from CALR deficient mice are functional but effectors T cells are less sensitive to suppression by 
their ability to produce pro inflammatory cytokines like IL-2. In line with this hypothesis, we 
compared the proliferative ability of CD4+CD25- T cells from CALR+ patients and HD. As 
predicted, CD4+CD25- T cells from patients showed increased proliferation as compared to HD 
the CD4+CD25- T cell population used in the assay 
carried the exon 9 CALR mutation (Figure 5F). 
In conclusion, we show that JAK2(V617F) mutated patients have an atypical composition in the 
Tregs compartment; moreover, the presence of CALR mutation in the effector T cells confer them a 




Figure 5. JAK2(V617F) mutated patients present a different Tregs heterogeneity in periphery. A) PB 
circulating number of Tregs (identified as CD3+CD4+CD25+CD127low cells) in HD (n=17), total MF 
(n=22), JAK2(V617F) mutated (n=11), CALR mutated (n=7) and triple negative (n=4) patients; cell 
concentrations were calculated as follows: (percentage of positive cells) x (lymphocyte count)/100. Each 
symbol represents one individual and the height of the bar represents the mean; B) Representative example 
of the gating strategy used to determine by flow cytometry, in HD (left panels) and MF patients (right 
panels), the percentages of CD3+CD4+CD45RA+CD25+CD127low (population I), CD3+CD4+CD45RA-
CD25brightCD127low (population II) and CD3+CD4+CD45RA-CD25+CD127- (population III) cells; C) 
Percentages of Population I, II and III in HD (n=14), total MF (n=16), JAK2(V617F) mutated (n=7) CALR 
mutated (n=5) and triple negative (n=4) patients.. Histograms represent mean percentage expression on the 
CD3+CD4+CD25+CD127- population ± SD; D) Co-colture (5 days) of autologous Treg from HD (n=9), 
JAK2(V617F) mutated (n=4) and CALR mutated (n=4) patients with autologous CD4+CD25- (Tresp) 
stimulated with anti-CD3 and anti-CD28 (5mg/mL) and labeled with CFSE. Percentage of proliferation was 
 
added)x100; histograms represent mean ± SD; E) Proliferation of CD4+CD25- from CALR mutated patients 
(n= 4) and HD (n= 4) stimulated with anti-CD3 and anti-CD28. Proliferation is calculated using the 
division index (average number of cell divisions that a cell in the original population has undergone); 
histograms represent mean ± SD; F) CALR exon 9 sequencing performed by Next Generation Sequencing to 
evaluate the variant allele frequency (VAT) expressed as percentages. Data indicate the percentages of 
mutated reads analyzed.  
Selected subsets of ILC with reduced functional capacity are expanded in MF 
patients 
ILC function is tightly regulated by cytokines, and uncontrolled activation and proliferation 
can contribute to severe inflammation. Due to the aberrant cytokine compartment in MF, we 
evaluated ILC frequencies, phenotype and function.  
The total ILC frequency was similar between MF patients and healthy controls (data not 
shown). We therefore analysed the relative frequency of the different ILC subsets as previously 
detailed (Figure 6A). We found that ILC1 and ILC3 NCR+ fractions were significantly increased in 
MF patients as compared to the normal counterparts (ILC1: 38±4.4% vs 27.16±2.6%; ILC3 NCR+: 
cells were significantly increased in JAK2(V617F) CALR+ patients showed an 
increased ILC3 NCR+ compartment (p<0.05). Interestingly, total ILC3 percentages were 
significantly higher in patients with intermediate-2/high IPSS score compared to those with 
low/intermediate-1 IPSS score (p<0.05). Moreover, we found a positive correlation between the 
percentages of ILC3 NCR+ and the circulating levels of IL-6 (R=0.51; p<0.04) (data not shown). 
Finally, we tested the functionality of ILCs by evaluating their cytokine producing capacity. 
Following short-term ex vivo activation, ILCs from MF patients showed dramatically impaired 
production of IFN- , IL-4, -5 and -13 (Figure 6C). In conclusion, we demonstrated that in MF the 























Figure 6. Selected subsets of ILCs with reduced functional capacity are expanded in MF patients. A) 
Representative example of the gating strategy used to determine by flow cytometry, in HD (upper panels) 
and MF patients (lower panels), the percentage of: ILC1 identified as Lin-CD127+CRTH2-cKit-CD56-
cells; ILC2 identified asLin¡CD127+ CRTH2+cKit+/- cells; ILC3 identified as Lin-CD127+CRTH2-
cKit+NKp46- cells that were further characterized by the expression of the natural cytotoxicity 
receptor(NCR). B) Histograms represent the percentages ± SD of selected ILC subpopulation in HD (n=21), 
total MF (n=23), JAK2(V617F) mutated (n=12) and CALR mutated (n=6) and triple negative (n=5) 
patients. C) PBMCs were stimulated ex vivo for 3 hours, then an intracellular staining was performed. 
Histograms represent the mean ± SD of the percentage of ILCs (Lin-CD127+cells) producing IFN-g, TNF-a, 








 [31] where the uncontrolled 
myeloproliferation and cytokine secretion creates a pro-inflammatory milieu influencing the 
immune system. Here we have demonstrated that several subsets of the adaptive and innate immune 
response show quantitative and/or qualitative abnormalities. Our data demonstrate how circulating 
mDCs, Th17, Th1, effectors Tregs, ILCs and cytokine plasma levels are dysregulated in our cohort 
of patients. Noteworthy, the presence of CALR or JAK2(V617F) mutation can affect this phenotype. 
Specifically, Th17, mDCs and Treg Population II reduction, associated with an increase in ILC1, 
was principally observed in the JAK2(V617F)+ group. Patients carrying CALR mutation present a 
dysregulated IFN- r, reduced circulating levels of INF-
reduction, hypofunctional ILC1 and mo-DCs. Notable, no association was found between allele 
burden and the number/phenotype/function of the studied cells. Furthermore, PET-MF and PV-MF 
did not show an immune pattern significantly different from PMF. 
Along with a reduced amount of circulating mDCs, we found an impaired ability of MF-
derived monocytes to differentiate in vitro toward DCs when cultured in the presence of IL-4 and 
GM-CSF. On monocytes, IL-4 receptor signals through JAK1/3 [32] while GM-CSF receptor 
through JAK2 and alternatively by IKK complex [33]. In MF, JAK2 constitutive activation confers 
to monocytes a high sensitivity to GM-CSF (commonly used in vitro for macrophages 
differentiation [34]) that results in a reduced capacity toward DCs differentiation and an increased 
macrophage-like phenotype. In line with these observations, 5 days cultured monocytes failed to 
fully down-regulate CD14 and presented a reduced expression of CD1a and CD80 compared to the 
normal counterpart. As a consequence, MF mo-DCs show a reduced capacity to stimulate T cell 
proliferation, and an enhanced endocytosis ability. In addition, mature mo-DCs from CALR+
patients continued to be defective in CD80 and CD40 molecules providing an incomplete co-
stimulatory signal essential for T cells activation and differentiation. These findings can explain, at 
least in part, the high infection rates seen in MF patients that are further exacerbated by ruxolitinib
[35], a JAK1/2 inhibitor affecting DCs differentiation and function in vitro [36]. 
DCs have the unique capacity to direct T cell differentiation through the strength of TCR 
interaction and cytokines present in the microenvironment. In MF we found a Th1 reduction that 
was detectable in CALR+ but not in JAK2(V617F)+ patients. IL-12 is a key factor for Th1 
differentiation; consistently, mature mo-DCs from CALR mutated patients show a reduced 
expression of CD40, a marker linked with DCs IL-12 production ability and Th1 differentiation in 
vivo [37,38]. 
The JAK2(V617F)+ group is characterised by Th17 reduction with an impaired context-dependent 
plasticity since the percentage of Th17/Th1 and Th17/22 populations were reduced compared to 
controls. In addition, effector Tregs are reduced as well. This population show a potent suppressive 
function in vivo, and it dies quickly on activation. We can hypothesize that this deficiency may be 
the result of increased apoptosis or conversion in the context of chronic inflammation. In fact, we 
observed a negative correlation between effectors Tregs and IL-12 plasma levels, a cytokine 
increasing the outgrowth of non-Tregs in vivo [39]. Of note, Tregs from CALR+ patients showed 
lower inhibition of autologous effector T cells proliferation than the normal counterpart. A more 
detailed analysis revealed that responder T cells, used in the assay, carried exon 9 CALR mutation 
conferring them an higher proliferative capacity in vitro. To our knowledge, a mutation in the T cell 
compartment in MF has been reported in MPN patients carrying JAK2(V617F)+  [40 42] , with no data 
available on CALR mutated patients.  
ILC rapidly respond to cytokines and microbial signals providing multiple pro-inflammatory and 
immuno-regulatory cytokines. Taking into account the aberrant cytokine production in MF we 
investigated the frequency of different ILC subsets. ILC1 and ILC3 NCR+ were increased in 
JAK2(V617F) and CALR mutated patients, respectively. Nevertheless, irrespective of the mutational 
status, ILCs were hypofunctional. In JAK2(V617F)+ patients, the increase of ILC1 can be explained 
considering the high IL-12 detected in circulation. This cytokine is essential for ILC1 differentiation 
and ILC2 conversion into ILC1 [43]. Equally, the ILC3 NCR+ increase could be linked to the high 
circulating level of IL- -23. Consistently, an ILC1 increase concomitantly with reduced 
functionality has been recently shown by us in patients with acute myeloid leukemia [18]. 
Noteworthy, total ILC3 percentages were significantly higher in patients with intermediate-2/high 
IPSS score indicating a possible role in Myelofibrosis progression. However, because of the current 
limited understanding in ILC biology, additional work needs to be performed to explain how the 









Although this study is based on a limited number of patients, this limitation can be easily 
addressed in multicentric studies aiming to monitor MF patients before and under treatment. Of 
note, our data highlight the importance of investigating in larger cohorts of patients the role of the 
immune system in MF and other MPNs according to the mutational status. 
Despite this limitation, this study gives an initial proof of concept that the immune landscape of MF 
varies among patients and that selected immune defects are principally associated with the presence 
of the JAK2(V617F) or CALR mutation. Overall, these abnormalities might contribute to the 
development of an immune defecting status with the potential to promote immune evasion, cancer 
progression and increased susceptibility to infections. In addition, a better understanding of the 


















MATERIALS and METHODS 
Patients samples and cell isolation 
EDTA-anticoagulated peripheral blood (PB) was obtained from 30 healthy age-matched 
volunteers and 33 patients with MF. Patients were at diagnosis (18 cases) or untreated for at least 
two months. The diagnosis of MF was made according to the WHO 2008 criteria (Table 1).  No 
patients were previously treated with Interferon-
Committee of the University Hospital of Bologna and was conducted in accordance with the 
Declaration of Helsinki. Patients/controls provided written informed consent for the study. PB 
mononuclear cells (PBMCs) were separated by Lympholyte 1.077g/cm3 gradient (Cedarlane; 
CL5020) stratification. Subsequently, highly purified CD4+CD25+, CD4+CD25- and CD14+ cells 
were isolated using specific immunomagnetic cell isolation Kits (Miltenyi Biotech, 130-050-201) 
according to manufacturer's instructions. 
 
Cell phenotype 
The circulating immune cells were evaluated in PB from patients and controls by 
multiparametric flow cytometry. Th17, Tregs, mDCs and pDCs, were identified as listed in Table 
S1 (see Additional tables). A minimum of 1x105 cells were acquired by flow cytometer BD Accuri 
C6 or FACSCanto (Becton Dickinson). Analysis was performed excluding cellular debris in a 
SSC/FSC dot plot. The percentage of positive cells was calculated subtracting the value of the 
appropriate isotype controls. Cell concentrations were calculated as follows: (percentage of positive 
cells) x (Lymphocyte count)/100 (Th17 and Tregs) or White Blood Cell counts/100 (mDCs and 
pDCs). PBMCs were used to assess the percentage of Th1, Th2, Th17/22, Th17/Th1, the three 
subpopulations of ILCs and Tregs. Gating strategy and antibodies used are listed in Table S1 (see 
Additional tables). The phenotype of circulating monocytes and monocyte-derived immature and 
mature DCs was also characterized (Table S1; see Additional tables). ILCs' cytokine production has 






Generation of monocyte-derived DCs 
Monocyte-derived DCs (mo-DCs) were generated by a 5-day culture of CD14+ cells in 
complete RPMI 1640 medium (Gibco-Invitrogen, BE12-167F) supplemented with 50 ng/mL 
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and 800 U/mL IL-4 (all from 
Endogen, 14-8339-62; 14-8049-80), at 37°C in 5% CO2, as previously described by us [21]. For 
maturation, day 5 mo-DCs were cultured for 48 hours in the presence of a pro-inflammatory 
cocktail: GM-CSF (50 ng/mL), IL4 (800 U/mL), IL6 (10 ng/mL; RIL6I RIL1BI), 
TNF- BMS301) and Prostaglandin (PGE)- 14-8129-62) (all from Endogen). 
 
Suppression assay 
To assess the inhibitory capacity of freshly-isolated Tregs, we set-up a Mixed Leukocyte 
Reaction (MLR). Briefly, 105 CD4+CD25- (Tresp) were labelled with Carboxyfluorescein 
succinimidyl ester (CFSE; Invitrogen; C34554), 5 M, according to the manufacturer's instructions. 
Tresp were co-cultured, for 5 days, alone or with autologous and irradiated (3000 cGy) Tregs at 
different Tresp/Treg ratios. MLR was set-up in 96-well plates pre-coated with anti-CD3 monoclonal 
antibody (mAb; clone UCHT1; BioLegend,; 317301) in presence of soluble anti-CD28 mAb (clone 
CD28; BioLegend; 302901). CFSE dilution has been exploited to assess cell division by flow 
dulate Tresp proliferation was analyzed 
using ModFit LTTM 3.1 calculating the upper generation proliferation index. 
 
Proliferation assay 
Allogeneic purified CD4+CD25- cells from healthy donors (HD) were labeled with CFSE 
and stimulated to proliferate by using immature mo-DCs (Tresp/DCs ratio 1:10) from HD and 
patients. The assays were carried out over a period of 5 days at 37°C and T cell proliferation was 
evaluated by flow-cytometry . 
 
Endocytosis assay 
Dextran uptake was measured by exposing 1x105 immature mo-DCs to fluorescein 
isothiocyanate (FITC)-conjugated dextran (0.5 mg/mL; Sigma Aldrich; 74817). Cells were 
incubated for 30 minutes at 37°C or on ice (used as a background control). After washing, 
fluorescence was analyzed by flow cytome -dextran was 




A total of 1x105 cells were seeded in a transwell chamber (diameter 6.5 mm, pore size 8 µm; 
Costar; Corning; CLS3464) in a 24-well plate and migration in response to CCL19 (400 ng/mL; 
Biolegend; 582104) was analyzed after 4 hours by Trypan Blue exclusion test. The amount of 
migrated cells was expressed as a percentage of the input: (number of migrated cells in the lower 
compartment/number of loaded cells in the upper compartment) x 100. 
 
Plasma levels measurement of selected circulating cytokines 
Selected cytokines plasma levels of patients/controls were measured by ELISA, according to 
the manu . The IL-17 ELISA kit was provided by Boster Immunoleader 
(Boster Biological Technology Co.; EK0430). The CiraplexTM immunoassay kit/Human 9-Plex 
Array (Aushon BioSystems, Cytokine 2 Array) was used for the measurement of various cytokines. 
 
Mutation analysis 
JAK2(V617F) allele-burden was assessed in granulocyte DNA with ipsogen JAK2 MutaQuant 
Kit (Qiagen, Marseille, France) on 7900 HT Fast Real Time PCR System (Applied Biosystem, 
Monza, Italy). CALR exon 9 sequencing was performed by Next Generation Sequencing (NGS) 
approach with GS Junior (Roche-454 platform; Roche Diagnostics, Monza, Italy); analysis was 
carried out with AVA Software (GRCh38 as referenced). Rare CALR mutations identified by NGS 
were confirmed by Sanger sequencing. MPL mutations were investigated by ipsogen MPLW515K/L




Chromosome banding analysis was performed on BM cells by standard banding techniques 
according to the International System for Human Cytogenetic Nomenclature. At least 20 
metaphases were required. Unfavorable karyotype, defined according the Dynamic International 
Prognostic Score System-plus (DIPSS) [22], included complex karyotype or single or two 
abnormalities including +8, -7/7q-, i(17q), -5%5q-, 12p-, inv(3) or 11q23 rearrangement. 
 
Statistical analysis 
Numerical variables have been summarized by their median and range, and categorical 
variables by count and relative frequency (%) of each category. All P values were considered 
 0.05 (2-tailed). Statistical analyses were performed with Graphpad (Graphpad
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Myelofibrosis (MF) is a clonal disorder of the hemopoietic stem cell. Beyond mutations in 3 
driver genes (JAK2, CALR and MPL), chronic inflammation is the hallmark of MF. Infections are 
one of the main causes of morbidity and mortality. Immune dysfunction, including T cells, natural 
killer and dendritic cells, which further aggravate after JAK1/2 inhibition therapy, has been 
described. In this scenario, monocyte contribution to the inflammatory microenvironment needs to 
be clarified.  To address the role of circulating monocytes within the inflammatory network of MF 
here we studied the in vitro and ex vivo functional behavior of monocytes from JAK2V617F
mutated MF patients in the presence or absence of in vitro/in vivo JAK1/2 inhibition. 
We found that MF monocytes show defective differentiation program and activation 
capacity. Furthermore, their in vitro ability to produce and secrete free and microvesicles-linked 
inflammatory cytokines is severely impaired under lipopolysaccharides stimulation. This might be 
due, at least in part, to the inhibitory activity of MF isolated microvesicles on the inflammatory 
cytokines secretion of monocytes under lipopolysaccharides stimulation.  Interestingly, in vitro and 
in vivo RUX therapy normalizes the monocyte chemokine expression and also their ability to 
produce intracellular and secrete microvesicles-bound inflammatory cytokines under 
lipopolysaccharides stimulation. 
In conclusion, our data demonstrate that in MF circulating monocytes are functionally 
defective. Of note, upon infectious stimulus, JAK1/2 inhibition reactivate the monocyte-driven 
inflammatory cytokine signaling suggesting that the mutated pathway has an inhibitory role. These 
findings may have therapeutic implications because they contribute to better interpreting the off-











Myelofibrosis (MF) is a clonal disorders of the hematopoietic stem/progenitor cell (HSPC) 
and may present as primary disease (PMF) or secondary to Essential Thrombocythemia (PET-MF) 
or Polycythemia Vera (PPV-MF). Typical clinical manifestations include debilitating systemic 
symptoms, progressive splenomegaly and transfusion-dependent cytopenia (1). 
JAK2, 
CALR, MPL) and more than 50% of patients carry a somatic mutation of JAK2V617F in 
hematopoietic cells. However, independently by the mutation status, a hyper-activation of the JAK-
STAT pathway, that transduces most hematopoietic and inflammatory cytokines, is observed (2). 
onic inflammation with abnormal release of pro-
inflammatory cytokines by activated leukocytes and megakaryocytes/platelets is considered the MF 
hallmark and it has been indicated as main contributor in MF initiation/clonal evolution. An 
abnormal expression and activity of several pro-inflammatory cytokines are associated with MF
phenotype and prognosis (3-7). More recently, it has been demonstrated that cytokine 
overproduction in MF myeloid cells is driven by multiple signaling pathways (NF-KB and MAPK) 
beyond JAK-STAT (8). Consistently, NF-KB signaling is hyperactivated in MF and contributes to 
myeloproliferation and inflammation (8, 9).  
Infections are one of the main causes of morbidity and mortality in MF, representing the 
cause of death in around 10% of the cases (10-13). The increased risk of infections is thought to 
arise from deregulation of key mediators of the immune system (14-21). To further aggravate the 
clinical landscape, prior studies have demonstrated significant inhibitory effects within the T cells, 
natural killer cells and dendritic cells after exposure to JAK inhibitors (22-27).  Of note, due to the 
involvement of multiple signaling pathways beyond JAK/STAT, MF cytokine overproduction is 
reduced but not abrogated by JAK1/2 inhibition with Ruxolitinib (RUX) (8).  
 Despite a key role in regulating inflammation and immune response, the role of monocytes 
in the pathogenesis of MF still needs to be fully addressed. Moreover, the impact of JAK1/2 
inhibition on monocyte behavior has never been investigated. Monocytosis may occur in patients 
with MF (around 15%) and is associated with poor outcome (28). Additionally, there is evidence 
that monocytes are over-activated (29, 30), show inflammatory features (31) and represents the 
principal cellular source for most inflammatory cytokines (8).  
 Extracellular vesicles (EVs), which are composed of microvesicles (MVs; 200-1000 nm) 
and exosomes (30-150 nm), are released from a broad variety of cells during homeostasis and cell 
activation with pleiotropic effects on signalling among cells. MVs affect normal and malignant 
hemopoiesis (32) and are critical players in the regulation of inflammation/immunity (33, 34). Prior 
study demonstrated that exosomes associated-cytokines, either surface-bound or encapsulated, can 
be detected in body fluids including plasma (35). High serum levels of MVs have been detected in 
haematological malignancies including MPN (36, 37) and we recently described that circulating 
monocyte-derived MVs are increased in MF (38). 
However, their role in the immune microenvironment of MF, especially on the function of specific 
subsets of immune cells, such as monocytes, has not yet been defined. 
To increase knowledge in the pathogenesis of the inflammatory/immune microenvironment of MF 
and to address the role of monocytes within this inflammatory network and in recurrent infections 
in MF, here we studied the in vitro and ex vivo functional behavior of monocytes from JAK2V617F
mutated MF patients and their ability to respond to an infectious stimulus, in the presence or 
absence of JAK1/2 inhibition. We also evaluated whether circulating MVs from patients may 















Circulating monocyte subsets of MF are dysregulated and their profile is 
not affected by in vivo RUX therapy   
 
 Based on the expression of CD14/CD16, monocytes can be classified into Classical-
CD14++/CD16-, Intermediate-CD14+/CD16+ and Non-Classical-CD14-/CD16++ monocytes
fractions. There is a gradual acquisition of the surface marker CD16 during maturation in 
intermediate monocytes, playing an inflammatory role, and Non-Classical monocytes, having an 
anti-inflammatory activity (39, 40).  
 We therefore analyzed in MF the ex vivo profile of the 3 different subsets before and after 
RUX therapy. As shown in Figure 1, at baseline only the mean percentages of Intermediate/Non-
Classical monocytes (B and C) were significantly increased/reduced as compared with the normal 
counterparts (p<0.05, respectively). In vivo RUX therapy did not significantly modify the monocyte 
subsets profile. 
 
Figure 1. Frequency of circulating monocyte subsets (Classical, Intermediate and Non-Classical, according 
to CD14/CD16 expression) in PBMCs of HD (n=30) and MF pts at baseline (MF baseline T0; n=30) and 
after 6 months of in vivo RUX therapy (MF RUX (T6m); n=20). Histograms represent the mean percentage 
of monocyte subsets in total CD14+ monocytes . 
 
 
Chemokine receptors expression of MF monocytes is dysregulated and 
in vivo RUX therapy normalizes the chemokine receptor repertoire 
 
 Chemokine-driven migration toward inflammatory/damaged tissues is a crucial monocyte-
related feature. We thus studied the expression of crucial chemokine receptors on total circulating 
monocytes and subsets from MF patients and HD.   
 CCR2, which play a role in the mobilization of monocytes from bone marrow to peripheral 
blood, is primarily expressed by Classical monocytes. During differentiation, CCR2 is 
progressively downregulated in the Intermediate and Non-Classical monocytes. Conversely 
CX3CR, which in turn plays a role in the migration of circulating monocytes from peripheral blood 
toward inflamed/damaged tissues, is upregulated in Intermediate and Non-Classical monocytes. 
CCR5, which is also involved in the migration to inflamed tissues, is expressed by all monocyte 
fractions. 
  In MF patients, at baseline, only CCR2 (percentage of positive cells, Figure 2A; MIF, 
Supplementary Figure 1A) and CCR5 expression (MIF, Supplementary Figure 1C) of total 
monocytes was significantly increased/decreased as compared with the normal counterparts 
(p<0.05, respectively). Analyzing the monocytes subsets, CCR2 expression was significantly higher 
in intermediate and Non-Classical monocytes as compared with the normal counterparts 
(percentage of positive cells, p<0.01 and p<0.001, Figure 2A; MIF, Supplementary Figure 1A,
p<0.05, respectively). Conversely, CX3CR1 expression of Intermediate and Non-Classical 
monocytes was significantly reduced (percentage of positive cells, Figure 2B, p<0.01, respectively; 
MIF, Supplementary Figure 1B p<0.05 and p<0.01, respectively,). CCR5 expression was always 
significantly reduced as compared with the normal counterparts (MIF, Supplementary Figure 1C,
p<0.05). 
 Interestingly, in vivo Ruxolitinib therapy normalizes the CX3XR1 expression of 
Intermediate and Non-Classical monocytes (percentage of positive cells, Figure 2B, p<0.05, 
respectively; MIF, Supplementary Figure 1B, p<0.05, respectively) and CCR5 expression of all 
monocytes subsets (p<0.05, respectively). Of note, there was the normalization of CCR2 expression
also in Intermediate and Non-Classical monocytes (percentage of positive cells, Figure 2A, p<0.05 
and p<0.01).  
 Collectively, these data demonstrated that in MF circulating monocytes show a dysregulated 
activation/differentiation program. Interestingly, in vivo RUX therapy normalizes the expression of 
crucial chemokine receptors. 
 
 
Figure 2. Crucial chemokine receptors (CCR2, CX3CR1, CCR5) expression  of total monocytes and of the 
three subsets (Classical, Intermediate and Non-Classical)  from PBMCs of HD (n=30) and MF pts were 
analysed at baseline (MF baseline T0; n=30)  and after 6 months of in vivo RUX therapy (MF RUX (T6m); 
n=20). 
 ***p<0.001; Mo=monocytes). 
 
Supplementary Figure1. Crucial chemokine receptors (CCR2, CX3CR1, CCR5) expression (MFI) of total 
CD14+ monocytes and of the three subsets (Classical, Intermediate and Non-Classical)  from PBMCs of HD 
(n=30) and MF patients  were analyzed at baseline (MF baseline T0; n=30) and after 6 months of in vivo 
RUX therapy (MF RUX (T6m); n=20). Histograms represent the mean MIF of CCR2, CX3CR1, CCR5 










MF monocytes subsets show a dysregulated inflammatory cytokine 
receptors expression and in vivo RUX therapy partially modifies the 
cytokine receptors repertoire 
 
 To evaluate how MF circulating monocytes sense the inflammatory microenvironment, we 
tested the expression of crucial pro/anti-inflammatory cytokine receptors on monocytes from 
pts/HD.   
 Figure 3 shows a decreased percentage of TNF-R1 positive (A; p<0.01) and an increased 
percentage of TNF-R2 and IL10-R positive total MF monocytes (B, C: p<0.01, respectively) as 
compared with the normal counterparts. Comparing subsets, the percentages of TNF-R1 positive 
cells from MF pts were significantly reduced in all subsets (Classical and Non-Classical monocytes, 
p<0.01 and Intermediate monocytes, p<0.001). No differences were observed for TNF-R2 
expression.  Conversely, the percentages of IL-10R positive cells were significantly increased in all 
subsets (p<0.01 (Classical monocytes), p<0.05 (Intermediate and Non-Classical monocytes)). In 
vivo RUX therapy normalized the percentages of IL10R positive cells in intermediate and non-
classical monocytes only. 
Of note, the percentages of IL- -6R positive total monocytes and monocyte subsets of 
MF pts were not significantly different from the normal counterparts (data not shown). However, as 
shown in Supplementary Figure 2, total monocytes of MF pts showed significant increased IL-
-6R expression (MIF; p<0.05) as compared with the normal counterparts. When 
-R (MIF; Intermediate and Non-Classical 
monocytes; p<0.05 and p<0.001) and IL6-R (MIF; Classical and Non-Classical monocytes; p<0.05, 
respectively) were significantly increased as compared with the normal counterparts and in vivo
RUX therapy does not affect  their expression. 
These results demonstrate that JAK2V617F mutation can alter the expression of inflammatory 
cytokine receptors and that MF monocytes may abnormally sense the pro/anti-inflammatory 
microenvironment. in vivo RUX therapy partially normalize their cytokine receptors profile. 
 
 
Supplementary Figure 2. Crucial pro-inflammatory cytokines receptors (IL-1 -R1, IL-6-R1) expression (MFI) of total 
monocytes (identified by CD14 expression) and of the three subsets (Classical, Intermediate and Non-Classical)  from 
PBMCs of HD (n=30) and MF patients at baseline (MF baseline T0; n=30)  and after 6 months of in vivo RUX therapy (MF 
RUX (T6m); n=20). Data are shown as mean MIF of IL-1 -R1, and IL-6-R . 
 
Figure 3. Crucial pro-inflammatory cytokines receptors (TNF- -R1, TNF- -R2, IL-10R) expression of total 
monocytes (identified by CD14 expression) and of the Classical, Intermediate and Non-Classical monocytes 
from PBMCs of HD (n=30) and MF pts (n=30) at baseline (MF baseline T0)  and after 6 months of in vivo 
RUX therapy (MF RUX (T6m); n=20) is shown.  Histograms represent the mean percentage of cytokine 
receptors-positive monocytes  
 
Selected activation markers are dysregulated in MF monocytes and in 
vitro and in vivo RUX treatment does not significantly modify their 
profile  
 
To evaluate whether MF monocytes are hyperactivated and whether RUX might influence 
monocyte activation, we analyzed ex vivo and in vitro the expression of crucial activation markers 
in immunomagnetically isolated monocytes from MF pts/HD in the presence/absence of LPS 
stimulation and of in vitro RUX treatment.  
As shown in Figure 4, at baseline only the mean percentages of IL-10R (D) and CD163 (E) 
positive MF monocytes were significantly increased/decreased (p<0.05, respectively), as compared 
with the normal counterparts.  
Upon LPS stimulation, no significant differences in HLA-DR, CD86, CD40 and IL-10R (Figure 4
A, B, C, D; both percentages and MIF (MIF data not shown)) were observed between HD and MF 
monocytes. Interestingly, LPS stimulation significantly decreased the mean percentages of CD163 
positive HD monocytes, but not MF monocytes, as compared with unstimulated cells (E; p<0.05). 
Thus, the percentages of CD163+ cells from MF pts was significantly increased as compared with 
the HD counterpart (p<0.05) (Figure 4). 
in vitro RUX treatment did not significantly modify CD86, HLA-DR, CD40, IL10-R and CD163 
expression (both percentages and MIF) of normal and MF total monocytes in the absence of LPS 
stimulation (data not shown). Accordingly, in vivo RUX treatment did not significantly modify the 
percentages of HLA-DR, CD86, CD40 and CD163 positive total MF monocytes as compared with 
baseline (data not shown); only the percentage of IL-10R positive cells was significantly reduced 
but not normalized (Figure 3C; p<0.05). 
When monocytes from HD and MF pts were stimulated with LPS (Figure 4), in vitro RUX 
treatment did not significantly modify the mean percentages of HLA-DR positive MF /HD 
monocytes (A). Conversely, the mean percentages of CD86 (B; 1 µM RUX), CD40 (C;10 µM 
RUX) and IL-10R (D; 0.2, 0.5, 1.5 µM RUX) positive monocytes from HD were significantly 
reduced as compared with RUX untreated cells (p<0.05, respectively).  Of note, in vitro RUX 
treatment significantly reduced the percentage of CD163 positive MF monocytes (Figure 4E; 0.2, 
1, 5, 10 µM; p<0.05, respectively) only (). 
These data demonstrate that the activation marker profile of MF monocytes is partially altered and 
that, with the exception of CD163, in vitro/in vivo RUX treatment does not significantly modify 
this repertoire. 
 
Figure 4. The expression of crucial markers of activation (HLA-DR, CD86, CD40, IL-10R, CD163) on 
immunomagnetically isolated monocytes from HD (n=20) and MF pts (n=20) in the presence or the absence 






The ability of MF monocytes to produce pro-inflammatory cytokines 
under LPS stimulation is reduced and in vivo RUX therapy normalizes 
this pattern 
 
Cytokine production represent the main mechanisms used by monocytes to respond to the external 
stimuli. We evaluated ex vivo the percentages of IL1- - -10 and IL-6 producing 
monocytes with/without LPS stimulation (4 hours) in HD and patients before and after 6 months of 
in vivo RUX therapy. No IL-10 positive cells were detected with/without LPS stimulation (4 hours; 
data not shown). 
As shown in Figure 5, in the absence of LPS stimulation the mean percentages of IL1-  (A), TNF-
 (B) and IL-6 (C) positive cells were very low and no differences were observed between HD and 
MF pts.  
LPS stimulation of MF monocytes failed to increase the percentages of IL1- - -6 
positive monocytes, which were therefore significantly reduced as compared with the normal 
counterparts (Figure 5; p<0.001, respectively).  Interestingly, in vivo 6 months-RUX therapy 
restored and normalized the mean percentages of IL1- - -6 positive monocytes after 
LPS stimulation. 
These data demonstrate an impaired ability of MF monocytes to produce inflammatory cytokines in 
response to an infectious stimulus and show that in vivo inhibition of JAK1/2 restores normal 
cytokine production ability. 
Figure 5. Intracellular expression of pro-inflammatory cytokines in total monocytes from HD (n=30) and 
MF (n=30) PBMCs (at baseline (MF baseline T0) and after 6 months of in vivo RUX therapy (MF RUX 
(T6m); n=20) with or without stimulation with LPS (4 hours) is shown. Histograms represent the mean 










Monocytes from MF patients show reduced ability to secrete selected 
pro/anti-inflammatory cytokines and in vitro, but not in vivo, RUX 
treatment modify this profile 
 
In parallel experiments we tested the concentrations of selected pro/anti-inflammatory cytokines in 
the supernatants of MF and HD monocytes upon LPS stimulation and before and after 6 months of 
in vivo RUX therapy. After LPS stimulation, normal monocyte activation involves the production of 
cytokines at different times points. As shown in Figure 6, the concentrations of IL-
hours; p<0.001)  TNF- -6 (C; 4 or 24 hours; p<0.01/p<0.001, 
respectively ) and IL-10 (D; 24 hours; p<0.001) in the supernatants of HD monocytes, were 
significantly increased after stimulation with LPS. Conversely, upon LPS stimulation, no significant 
differences were observed between stimulated and unstimulated MF monocytes. As a consequence, 
at baseline the concentrations of IL- -
IL-6 (C; 4 or 24 hours; p<0.01) and IL-10 (D; 24 hours; p<0.001) were significantly reduced in the 
supernatants of MF monocytes as compared with the normal counterparts. Of note, 6 months of in 
vivo RUX therapy did not significantly modify the concentrations of the 4 selected cytokines in the 
supernatants of MF monocytes (Figure 6). 
 We then functionally analyzed the effects of in vitro titrating doses of RUX on the ability of 
isolated MF or HD monocytes to release crucial pro-anti-inflammatory cytokines in the 
supernatants of cultures upon LPS stimulation. As shown in Figure 7, the IL-6 and IL-
concentrations in the supernatants from HD or MF monocytes were not significantly modified by 
increasing doses of RUX (Figure 7 A, B, E, F) as compared with untreated cells. By contrast, RUX 
dose-dependently reduced the IL-10 concentration in the supernatants from MF (0.2, 0.5, 1, 5, 10 
µM; p<0.05/p<0.01) or HD (1, 5, 10 µM; p<0.05/p<0.01; Figure 7 G and H) monocytes.  
Interestingly, low dose RUX treatment significantly increased the concentration of TNF-
supernatants from HD (0.2, 0.5, 1 µM) and MF (0.5, 1 µM) monocytes (Figure 7 C and D) (p<0.05, 
respectively). Conversely, high dose RUX (10 µM) significantly decreased the concentration of 
TNF- d MF monocytes (p<0.05, respectively). 
Collectively, these results indicate a reduced ability of MF monocytes to secrete inflammatory-
related signals and demonstrate that in MF, in vitro, but not in vivo, RUX treatment distinctly 




Figure 6. Concentrations of crucial pro (IL-1 - , IL-6)/anti (IL-10)-inflammatory cytokines in the 
supernatants of immunomagnetically isolated monocytes from HD (n=20) and MF pts (n=20) (at baseline 
(MF baseline T0) and after 6 months of in vivo RUX therapy (MF RUX (T6m); n=20 ) in vitro cultured for 
4/24 hours in the presence or absence of LPS stimulation. Histograms represent the mean concentration of 









Figure 7. Concentrations of crucial pro (IL- - , IL-6)/anti(IL-10)-inflammatory cytokines in the 
supernatants of immunomagnetically isolated monocytes from HD (n=20;panels A, C, E, G) and MF pts 
(n=20; panels B, D, F, H)  in vitro cultured for 24 hours in the presence or absence of LPS stimulation and 
titrating doses of RUX (0.2-10 µM). Histograms represent the mean concentration of IL- - , IL-6 and 
IL-10 . 
The expression of pro-inflammatory cytokines on the surface of 
monocyte-derived MVs from MF patients is reduced and in vivo/in vitro 
RUX treatment normalizes their profile  
 
To investigate the surface associated-cytokines of monocyte-derived MVs and whether RUX 
treatment may affect their profile, we analyzed the presence of selected pro/anti-inflammatory 
cytokines on the surface of MVs produced by HD and MF monocytes (at baseline and after in 
vivo/in vitro RUX treatment).  As shown in Figure 8, in the absence of LPS stimulation, no 
significant differences were observed between pts and HD or before and after in vivo RUX therapy. 
When monocytes were stimulated with LPS, the percentages of IL-6, , TNF- -10-positive 
MVs of MF pts were significantly decreased as compared with the HD counterparts (Figure 8 A, B, 
C, D; p<0.001, respectively). Interestingly, there was a trend, albeit non statistically significant, 
toward increased percentages of cytokines-positive MVs after in vivo RUX treatment. Consistently, 
after LPS stimulation, in vitro RUX treatment significantly increased the percentages of , TNF-
-6 and IL-10-positive MVs in the supernatants of isolated monocytes from MF pts at baseline 
(Figure 9 A, B, C, D). Interestingly, no effects were observed after LPS stimulation alone.  
Collectively, these results demonstrate that in MF the MVs-related pro/anti-inflammatory signals of 




Figure 8. The expression of  surface-bound IL- TNF- , IL-6 and IL-10 positive MVs in the supernatants 
of immunomagnetically isolated monocytes from HD (n=20) and MF pts  (n=20; at baseline (MF baseline 
T0) and after 6 months of in vivo RUX therapy (MF RUX (T6m); n=20), in the presence/absence of LPS 







Figure 9. Surface-bound IL- TNF- , IL-6 and IL-10-positive MVs in the supernatants of 
immunomagnetically isolated monocytes from MF pts (n=20) in the presence or the absence of LPS 
stimulation (24 hours) and titrating doses of in vitro RUX treatment is shown. Histograms represent the 







in vitro RUX treatment inhibits the ability of monocytes from MF 
patients or HD to promote T cells proliferation/activation  
To investigate whether RUX may affect the ability of monocytes from pts/HD to activate CD4+ T 
cells, we co-cultured monocytes and autologous CD4+ T cells in the presence of anti-CD3 
stimulation and we analyzed the percentage of proliferating T cells. As shown in Figure 10A, RUX 
(0.2, 0.5, 1, 5, 10 µM) significantly reduced the ability of HD and MF monocytes to promote the 
proliferation of T cells (p<0.05, respectively). This reduction was associated with a significant 
decrease of the expression of early (CD69; 10B) and late (CD25; 10C) markers of activation in T 
cells from HD (CD69 and CD25) and MF patients (CD25 only).  
These results demonstrate that MF monocytes are capable to fully activates autologous CD4+ T 
cells; however, in vitro RUX treatment inhibits this ability. 
 
Figure 10. Ability of immunomagnetically isolated monocytes from HD (n=10) or MF pts at baseline (n=10) 
to stimulate T cells proliferation in the presence or the absence of in vitro RUX treatment. After LPS pre-
stimulation of monocytes, we performed co-cultures of immunomagnetically isolated monocytes and 
autologous CFSE-labeled CD4+ T cells (monocytes-CD4+ T cell ratio 1:1) in the presence of CD3 
stimulation and titrating doses of RUX for 5 days.   The proliferation of CD4+ T cells was evaluated by flow 
cytometry (A). The expression of selected activation markers of CD4+ T cells such as CD69 (B; 24h) and 




Isolated MVs from PPP of MF patients decrease the in vitro secretion of 
pro/anti-inflammatory cytokines from HD monocytes upon LPS 
stimulation 
 
To evaluate whether circulating MVs may affect the ability of normal monocytes to secrete 
pro/anti-inflammatory cytokines we performed in vitro co-cultures of immunomagnetically isolated 
HD monocytes with isolated MVs from PPP of HD or MF pts, in the presence or the absence of 
LPS stimulation. As shown in Figure 11, in the absence of LPS stimulation, MVs from HD or MF 
pts did not affect the secretion of pro/anti-inflammatory cytokines from HD monocytes in the 
supernatants.  Interestingly, after LPS stimulation, only MVs from MF patients significantly 
reduced the concentrations of pro (IL-6; p<0.01, TNF- -10; p<0.05)-inflammatory 
cytokines in the supernatants. No differences were observed in the IL-
shown). 
These data demonstrate that circulating MVs from MF patients do not affect the pro/anti-
inflammatory cytokines secretion of normal monocytes; however, in the presence of an infectious 




Figure 11. Concentrations of pro/anti-inflammatory cytokines (TNF- , IL-6 and IL-10) in the supernatants 
of immunomagnetically isolated HD monocytes (n=15) in vitro cultured with or without LPS stimulation (24 
hours) and allogeneic isolated MVs (1/100 monocyte/MVs ratio) from HD and MF pts at baseline.











Immune dysregulation is a common feature of patients with MF. JAK1/2 inhibitors therapy 
further aggravates this pattern. This results in impaired immunosurveillance which is associated to 
the occurrence of infectious complications with unusual site and type of disease (10-27).  
  Here we demonstrated that in JAK2V617F mutated MF patients the monocyte 
differentiation program is dysregulated as referred to subsets population profile and 
chemokine/cytokine receptors repertoire. Of note, in vivo RUX therapy distinctly normalize this 
behaviour, suggesting that the RUX therapy, reducing plasma inflammatory cytokines, may 
indirectly support monocyte homing to inflamed/damaged tissue through CX3CR1 and CCR5
upregulation. Conversely, the downregulation of CCR2 may promote monocyte mobilization from 
bone marrow to peripheral blood. 
 We have also found that in vitro the intra-cellular pro-inflammatory cytokine production of 
unstimulated MF monocytes is low and superimposable to the normal counterparts. Thus, our data 
suggest that the contribution of steady-state monocytes to the inflammatory microenvironment of 
JAK2V617F mutated MF is low. This finding is in contrast with Fisher DAC et al (8) showing that 
14/15 cytokines measured by mass cytometry were found to be constitutively overproduced in MF, 
with the principal cellular source for most cytokines being monocytes. Whether this is due to the 
fact that different techniques have been used (mass cytometry vs traditional flow cytometry 
analysis) or to the fact that their analysis focused on cytokine produced by CD14 high monocytes 
only remains a matter of discussion. 
 Upon LPS stimulus, the in vitro intracellular production and secretion of pro/anti-
inflammatory cytokines by monocytes of JAK2V617F mutated MF pts was severely impaired. Of 
note, recent study has shown that the binding of TNF-
proinflammatory cytokines via TNF-R1 and the binding through TNF-R2 upregulates the anti-
inflammatory cytokine, IL-10, in the absence of any upregulation of proinflammatory cytokines 
(41). This study supports our hypothesis that the reduced ability of MF monocytes to produce 
inflammatory cytokines in response to infections stimuli might be due, at least in part, to the 
reduced frequency of circulating TNF-R1 positive monocytes. Furthermore, we can not also rule 
out the hypothesis that, in MF, monocytes might be exhausted by the continuous stimulus of the 
inflammatory microenvironment.  
Importantly, in the absence of LPS stimulation, allogenic isolated circulating MVs from 
JAK2V617F mutated MF pts and HD failed to in vitro activate normal monocytes. When LPS
stimulation occurred, isolated circulating MVs of MF pts, but not those of HD, inhibited the in vitro
pro-inflammatory cytokines secretion of normal monocytes. This finding suggests that the 
decreased ability of monocytes from JAK2V617F mutated MF pts to secrete inflammatory 
cytokines might be due, at least in part, to a MVs-driven mechanism of inhibition.  
Interestingly, in vivo RUX therapy promoted the in vitro LPS-driven intracellular cytokines 
production, but not secretion, of monocytes from JAK2V617F mutated MF patients. Moreover, we 
provided also evidence that, upon in vitro LPS stimulus, the frequency of monocyte-derived MVs 
expressing surface pro/anti-inflammatory cytokines is strongly reduced. Importantly, in vitro and in 
vivo RUX treatment increases their proportion. Thus, JAK1/2 inhibition restores cytokine 
production and MVs-driven inflammatory signaling of MF monocytes. LPS-driven-cytokines 
production of monocytes is activated by MyD88 transduction signaling pathway (42); therefore, 
these data support the hypothesis that, upon LPS stimulus, the cytokines production by monocytes 
is JAK1/2 signaling independent. We can also hypothesize that the decrease of plasma 
inflammatory cytokines after JAK1/2 inhibition therapy may favour MF monocyte regeneration and 
activation. 
Our findings are consistent with a prior study demonstrating that isolated circulating 
monocytes from MF fail to respond to LPS and the levels of pro-inflammatory cytokines such as 
IL23, IL12 and TNF- -8 (31).  
On the other hand, we are in contrast to a recent report (43) showing that monocytes from 
patients with MPN have defective negative regulation of Toll-like receptor (TLR) signalling leading 
to unrestrained production of TNF-
monocytes of patients with MPN are insensitive to IL-10 which negatively regulates TLR-induced 
TNF- iscrepancy is due to the fact that Lai YH et al. studied, in 
addition to MF, also ET and PV monocytes remains a matter of discussion. Nevertheless, according 
to the present study, they also demonstrated that, upon LPS stimulation, the percentage of TNF-
monocytes were significantly decreased in MPN.  
In conclusion here we demonstrated that circulating monocytes from JAK2V617F mutated MF 
patients are dysregulated and show a reduced in vitro ability to produce/secrete inflammatory 
cytokines in response to an infectious stimulus. These findings suggest that monocytes are not the 
principal source of inflammation in JAK2V617F mutated MF patients and that this monocyte 
dysfunction may result in altered immune surveillance against infectious complications or cancer.
Importantly, in vivo/in vitro JAK1/2 inhibition ameliorates their cytokines production and promotes 
the MVs-based inflammatory cytokine signaling. Therefore, we can not draw the conclusion that in 
MF infections occurring following exposure to JAK1/2 inhibition are due to monocyte 
compartment dysregulation.  
Finally, our findings may have therapeutic implications because they contribute to better 
interpreting the off-target efficacy of JAK1/2 inhibition in MF and to envisaging strategies aimed at 














MATERIALS and METHODS 
 
Patients samples and cell isolation 
EDTA-anticoagulated peripheral blood (PB) was collected from JAK2V617F mutated MF patients 
(pts) before (n=30) and after 6 months of Ruxolitinib (RUX) therapy (n=20) and from age/sex-
matched healthy donors (HD; n=30). Pt characteristics are shown in Table I. Pts were at diagnosis 
or at least after 3 months from cytotoxic therapy. This study was approved by the local Ethical 
Committee and was performed according to the declaration of Helsinki. Pts/controls signed 
informed consent.  
After discarding the first 2 ml of blood, Platelet Poor Plasma (PPP) was obtained (within 2 hours 
from blood collection) after centrifugation at 2500g for 15 minutes at room temperature and then 
stored at -80°C with 1% of dimethyl sulfoxide (DMSO). PB mononuclear cells (PBMCs) were 
separated by Lympholyte 1.077g/cm3 gradient (Cedarlane; CL5020) stratification, cryopreserved in 
liquid nitrogen and then thawed at 37°C before testing. Of note, to minimize the influence of 
freezing/thawing, only thawed PBMCs with a survival rate > 80% were used. 
 
CD14+ monocytes and CD4+ T cells Isolation 
Circulating CD14+ cells were immunomagnetically isolated from thawed PBMCs of MF pts (at 
baseline and after 6 months of RUX therapy) and HD using a commercially available kit (CD14 
Isolation kit, human; Miltenyi Biotec, Bologna, Italy) and purity (95 ± 3%) was routinely checked 
by flow cytometry. After monocytes isolation, circulating CD4+ T lymphocytes cells (CD4+ T 
cells) were immunomagnetically isolated from CD14- PBMCs using a commercially available kit 
(CD4+ T Cell Isolation Kit, human; Miltenyi Biotec, Bologna, Italy) and purity (93 ± 4%) was 








Phenotype of Monocytes  
Total monocytes and subsets (Classical- CD14++/CD16-, Intermediate- CD14+/CD16+, Non-
Classical-Mo CD14-/CD16++) were phenotypically characterized by flow cytometry (chemokine 
receptors: C-C chemokine receptor type 2 (CCR2), C-X3-C motif chemokine receptor 1 (CX3CR1), 
C-C chemokine receptor type 5 (CCR5); cytokine receptors: Tumor Necrosis Factor (TNF)-
TNF- IL)-10R, IL- -6R) in PBMCs from MF pts at baseline and after 6 
months of RUX therapy and HD (chemokine receptors/cytokine receptors panels are shown in 
Table 2). All flow cytometry analysis were performed on a FACSs Canto II (BD Biosciences) and 
analysed using FlowJo (FlowJo, LLC) (Gating Strategy 1 A, B, D, E, F is shown in 
Supplementary materials). 
 
Functional assay of monocytes in the presence or the absence of in vivo RUX 
therapy 
PBMCs from MF pts at baseline and after 6 months of RUX therapy and HD were stimulated with 
lipopolysaccharides (LPS, 100 ng/ml) in the presence of 5 ng/ml Brefeldin A (Sigma-Aldrich®) for 
4h. After in vitro stimulation, PBMCs were incubated with anti-CD14 and anti-CD16 monoclonal 
antibodies for 15 minutes at room temperature. Cells were then fixed/permeabilized according to 
standard procedures (IntraPrep Permeabilizaton kit, Beckman Coulter® Life Sciences) and IL-
IL-6, and TNF- oducing monocytes were measured by intracellular flow cytometry analysis  
(Gating Strategy 1A, 2 is shown in Supplementary materials; Intracellular Cytokine Production 
Panel is shown in Table 2). In parallel experiments, immunomagnetically isolated monocytes from 
pts/HD were stimulated with LPS (100 ng/ml), on the same day. After 4/24h, culture supernatants 







Functional Assay of Monocytes in the presence or absence of in vitro RUX 
treatment 
 
To investigate the in vitro biological/functional effects of RUX, circulating monocytes from MF pts 
and HD have been immunomagnetically isolated. We analysed by flow cytometry the effect of 
titrating doses (0.2-10 µM) of RUX (1) on the expression of crucial monocytes activation markers 
(CD86, HLA-DR, CD40, CD163, IL10R; Activation markers panel 1/2 is shown in Table 2) after 
24 hours of incubation in the presence or absence of LPS (100 ng/mL); (2) on the monocyte-derived 
pro-anti/inflammatory cytokines production (TNF- -6, IL-10 and IL-  (3) on the expression 
of surface-bound inflammatory cytokines expression of monocyte-derived MVs in the supernatants 
of cultures (24 hours); (4) the effect of  titrating doses of RUX  (0.2-10 µM) on the capacity of MF 
and HD monocytes to activate autologous CD4+ T cells. Specifically, after LPS pre-stimulation of 
monocytes (4hours), co-cultures of immunomagnetically isolated monocytes and autologous CD4+ 
T cells (Mo:CD4+ ratio 1:1) in the presence of CD3 stimulation (5ng/ml; CD3 Monoclonal 
titrating doses (0.2-10 µM) of RUX for 5 
days have been performed. CD4+ T cells were previously labelled with Carboxyfluorescein 
succinimidyl rogen; C34554), according to the manufacturer's instructions. 
The proliferation (CFSE assay) and the expression of selected activation markers such as CD69 
(after 24h of co-cultures) and CD25 (after 5 day of co-cultures) of CD4+ T cells were analysed by 
flow cytometry (Tcell Activation markers panel is shown in Table 2).  
 
 
Isolation of circulating MVs 
 
Circulating MVs were isolated from cryopreserved pts/HD-PPP. Briefly, after thawing at 37°C, the 
PPP was centrifuged at 1000g for 15 minutes to eliminate further cellular or fibrin contamination. 
The PPP was then diluted with a double filtered saline solution (0.22 µm) up to a final volume of 20 
ml and placed in ultracentrifuge tubes. The ultracentrifugation was performed by Optima L-90K 
(Beckman Coulter) at 45,000 rpm for 2 hours at 4°C. After ultracentrifugation, the supernatant was 
eliminated, and the MVs pellet was resuspended in 3
The isolated MVs were stored at -80°C after addition of 1% DMSO. The quantification of MVs was 
carried out by Nanosight instrument (NS300, Malvern Instruments Ltd, UK) to obtain the number 
of MVs/ml. 
 
MVs and monocytes co-cultures 
 
To evaluate the functional effect of circulating MVs on the production of cytokines by monocytes, 
co-cultures of immunomagnetically isolated HD-Mo and isolated MVs from MF pts and allogeneic 
HD have been performed, in the absence/presence of LPS. Specifically, monocytes were seeded 
(106/ml) in 12 wells plates with twice filtered RPMI (filter 0.22 µm) in the presence/absence of 
MVs and with/without LPS stimulation (100 ng/ml). The MVs were added at different 
monocytes/MVs ratio (1/100; 1/1000; 1/10000). After 4/24 hours of incubation at 37°C and 5% 
CO2, supernatants of monocytes were obtained after centrifugation at 400g for 5 minutes and stored 
at -80 ° C. The supernatants were then analyzed by flow cytometer to evaluate the concentration of 
IL- -6, TNF- -10. 
 
Cytokine concentration of the monocyte cultures supernatants  
Supernatants from monocytes cultures, with/without RUX (in vivo/in vitro), and HD-Mo/MVs co-
cultures (in the presence or absence of LPS stimulation (4/24h)) were harvested (centrifugation at 
400g) and frozen at -80°C with 1% of DMSO until assays were performed. Cytokine concentration 
was determined by commercially available MACSPlex Cytokine 12 Kit (Miltenyi Biotec, Bologna, 
Italy) for human IL-6, TNF- - -
determined by Human IL-1 beta/IL-1F2 Quantikine ELISA Kit; R&D Systems. 
 
surface of MVs from monocyte culture supernatants 
 
Cytofluorimetric analysis and staining method was developed to study the expression of surface
attached pro/anti-inflammatory cytokines in MVs from monocyte culture supernatants in the 
presence/absence of LPS stimulation and with/without RUX (in vivo/in vitro
were incubated with anti- - - - -
monoclonal antibody for 30 minutes at room temperature and then MVs were analyzed by flow 
cytometry (Navios, Beckman Coulter, Milan, Italy) (Cytokine-bound MVs Panel is shown in Table 
2).  To detect MVs the instrument was calibrated with MegaMix Beads (Stagò, Marseille, France). 
Fluorescence gated polystyrene beads of different sizes were used to determine the gates identifying 
big (500-900 nm), small (200-300 nm) and nano (100-160 nm) MVs. The Violet Side Scatter laser 
(VSSC) is used as a trigger signal to discriminate the noise. Big MVs identification was based on 
size (500-900 nm) and on the ability to bind specific monoclonal antibodies. Gating strategy to 
identify big MVs (500-900 nm) is shown (Gating Strategy 3, in Supplementary materials). 
Matched isotype controls were used to select the cut-off. Using the defined gate for big MVs, all 
events positive for markers staining were recorded. The expression of the pro/anti-inflammatory 
cytokines was expressed as percentage of positive MVs. 
 
Statistical analysis 
Statistical analyses were performed with GraphPad (GraphPad Software Inc., La Jolla, USA). Data 
are expressed as mean ± SEM. P values were -tailed). The 
differences between the groups were analysed with Mann Whitney, Kruskal Wallis, one-way and 

















Inflammation plays a very important role in cancer, including blood cancer. 
iferation and cytokine 
overproduction creates a pro-inflammatory microenvironment influencing the HSC/HSPC 
compartment and the immune system. Along with a role as activators of immune cell function, a 
growing evidence now demonstrates that proinflammatory cytokines strongly affect the size and 
lineage distribution of the blood cells via reprogramming of HSC/HSPC and supporting the bone 
marrow niche. Based on this evidence, it is very important to clarify the impact of proinflammatory 
cytokines on the biology of the normal HSPC and its BM microenvironment. A better 
understanding of the role and effects of inflammatory cytokines in the signals between HSPC and 
their inflammatory microenvironment would help to understand the mechanisms underlying 
tumorigenesis, particularly in hematological diseases and MF.  
In addition to the inflammatory cytokines, other components of the inflammatory network may play 
a role in MF pathogenesis. Among the possible mechanisms of development/propagation of 
inflammation and tumorigenesis, it has been described that the contribution of MV is crucial. The 
MV, expressing antigens and containing constituents from the cell of origin, are part of a 
mechanism that supports cellular communication, with the potential to influence the short and long-
distance microenvironment. Focusing on the inflammatory microenvironment that characterizes 
MF, the study of circulating MV would allow to deepen and understand the inflammatory pathways 
activated in the MF and to identify possible therapeutic targets. 
The importance of immune cells should not be underestimated. They are the main regulators of the 
inflammatory microenvironment, producing pro/anti-inflammatory cytokines in response to 
infectious/inflammatory stimuli and are also the cells mainly and functionally influenced by the 
inflammatory regulatory effects. A better understanding of the immune biology in the setting of MF 
would be important to understand if atypical infectious events in MF are caused by deficits in the 
innate or adaptive immune response and for the design of new therapies.
Among the targets of the JAK1/2 inhibitor Ruxolitinib, we hypothesized that circulating MV, being 
involved in inflammation, and monocytes, given the importance of the JAK-STAT pathway in their 
differentiation/function, could be strongly influenced by Ruxolitinib.  
Based on this background, the present thesis aimed: 1) to study the unexplored mechanisms that 
regulate the interaction between healthy HSPCs and their microenvironment; 2) focusing on MF, to 
investigate the immune/inflammatory microenvironment and characterize the pathogenetic role of 
crucial components of this inflammatory network, such as circulating MV, and specific subset of 
key immune cells.  
 
Specifically: 
1) we found that various combinations of inflammatory cytokines (IL- - -6, TIMP-1) 
promote in vitro survival of CB-derived CD34+ cells and increase proliferation, clonogenic ability
and in vitro migration of mPB-derived CD34+ cells. Inflammatory cytokines combined with bone 
marrow MSC promote the survival/migration of CD34+ cells from both sources. These results 
suggest that the inflammation and signal balance between HSPC and their microenvironment play a 
very important role in the functional behavior of normal HSPCs; suggesting that the modulation of 
this balance might be a clinically relevant approach in hematological malignancies. However, 
critical steps are involved in these processes and further insights are necessary to better understand 
HSPCs homing and engraftment. 
2) we found that in MF the profile of circulating MK/PLT derived MV is altered. Specifically, MK-
MV and PLT-MV were respectively decreased/increased, in MF patients as compared to the normal 
counterparts. This finding suggests that the altered MK/PLT-MV profile might be due to the
impaired megakaryocytopoiesis and platelets activation, which have been previously described in 
MF. Furthermore, according to IPSS score, Intermediate 2/high risk pts showed a respectively
reduced/increased MK-/PLT-MV proportions, as compared with the intermediate1/low risk group.
We also found that Ruxolitinib (JAK1/2 inhibitor) therapy restores the normal MK/PLT-MV profile 
of spleen-responders patients only, suggesting that constitutive activation of JAK/STAT pathway 
plays a role in the biogenesis/clearance of MV. Importantly, a cut-off value of 19.95% of MK-MVs 
discriminated the non-responders patients. Therefore, even though to be confirmed in a larger 
casistic, the MK/PLT-MV profile in MF can be used to predict the response to Ruxolitinib therapy 
and could have a diagnostic and prognostic role in MF. Further characterization demonstrated that
the miR cargo of circulating MF-MV shows upregulation of 4 miRs (-212/-127/-222/-34a) which 
are involved in apoptosis and that regulate inflammation and proliferation. Furthermore, we also 
identified a 1-miR signature with the potential to differentiate TN- and JAK2-MV. Therefore, this 
study has the potential to identify disease-related biomarker(s) and may provide a useful molecular 
target for MF diagnosis and treatment.  
3) we found that MF patients are characterized by a state of mutation-dependent immune alterations 
with key cellular components of the innate and adaptive immunity showing defective number and 
function. MF patients were characterized by a reduced ability of monocytes to differentiate into 
dendritic cells, reduced plasticity of Th17 lymphocytes and reduced functional capacity of ILCs. 
Analyzing the results by mutational status, we demonstrate that the MF immune microenvironment 
varies between patients and selected immune defects are mainly associated with the presence of the 
JAK2 or CALR mutation. Overall, these abnormalities could contribute to the development of an 
immunodeficiency state with the potential to promote immune evasion, cancer progression and 
increased susceptibility to infection. Although this study is based on a limited number of patients, 
our data highlight the importance of investigating the role of the immune system in MF and other 
MPNs according to mutational status in larger cohorts of patients. Furthermore, a better 
understanding of immune biology in the setting of MF would be important for the design of new 
MF therapies. 
4) we found that MF monocytes show defective differentiation program and activation capacity. 
Furthermore, their in vitro ability to produce/secrete free and microvesicles-linked inflammatory 
cytokines in response to an infectious stimulus is severely impaired. This might be due, at least in 
part, to the inhibitory activity of circulating MF isolated-MV on the inflammatory cytokines 
secretion of monocytes under lipopolysaccharides stimulation. Our data demonstrate that in MF, 
circulating monocytes are functionally defective. Furthermore, these findings suggest that 
monocytes are not the principal source of inflammation in JAK2-MF pts and support the hypothesis 
that the cytokines production by MF monocytes is JAK1/2 signalling independent. Interestingly, in 
vitro/in vivo Ruxolitinib therapy normalizes the monocyte chemokine expression and improves their 
cytokine production in response to an infectious stimulus, promoting the release of inflammatory 
cytokines associated with monocyte-MV. Upon infectious stimulus, JAK1/2 inhibition reactivates
the monocyte-driven inflammatory cytokine signalling, suggesting that: 1) the mutated pathway 
may have an inhibitory role; 2) the decrease of plasma inflammatory cytokines after JAK1/2 
inhibition therapy may favour monocyte regeneration and activation. Therefore, we can not draw 
the conclusion that in MF infections, occurring following exposure to RUX, are due to monocyte
dysregulation. This finding further refines the effects of Ruxolitinib on the MF immune system and 
suggests that Ruxolitinib activity is cell type-dependent. These findings may have therapeutic 
implications because they contribute to better interpreting the off-target efficacy of JAK1/2 






Taken together, the results of this thesis: 
1) Further characterize the promoting effects of combined inflammatory factors on the HSPC 
functional behaviour 
2) Increase knowledge on the profile and cargo of circulating MV of MF and identify the 
circulating MV as diagnostic and prognostic biomarkers in MF 
3) Increase knowledge on the immune dysfunction of MF 
4) Discover promoting effects of the JAK1/2 inhibitor Ruxolitinib on monocyte function 
 
In conclusion, this thesis provides scientific advances in understanding the functional role of the 
immune/inflammatory microenvironment in the pathogenesis of MF. Therefore, in MF, both the 
pathogenetic hypothesis and the therapeutic attempts should take into consideration not only the 
malignant clone but also the microenvironment, including soluble proinflammatory factors, signals 
mediated by immune cells and circulating MV. Understanding the mechanisms altering the 
interaction between the malignant clone and its microenvironment has the potential to promote the 
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